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I. RECOMMENDATIONS FOR AN o-TOLIDINE STANDARD
NIOSH recommends that employee exposure to o-tolidine in the workplace be 
controlled by adherence to the following sections. The recommended standard 
is designed to protect the health and provide for the safety of employees for 
up to a 10-hour workshift, 40-hour workweek, over a working lifetime. 
Compliance with all sections of the recommended standard should prevent 
adverse effects of o-tolidine on the health of employees and provide for their 
safety. The standard is measurable by techniques that are reproducible and 
available to industry and government agencies. The employer should regard the 
recommended workplace environmental limit as a maximum limit for exposure and 
should make every effort to keep the exposure as low as is technically 
feasible. Sufficient technology exists to permit compliance with the 
recommended standard. The criteria and standard will be subject to review and 
revision as necessary.
o-Tolidine is widely used in the dye industry. It is also used in 
analytical chemistry procedures, including tests for chlorine in water, and in 
medical laboratory tests for sugar or occult blood. The biologic dye, trypan 
blue, contains the o-tolidine moiety. Animals exposed to o-tolidine have 
developed cancers at various sites, and results of bacterial tests indicate 
that o-tolidine may be mutagenic. Damage to mammalian DNA metabolism has also 
been reported. o-Tolidine is readily absorbed through the skin, and nasal 
irritation has been reported in humans exposed to it.
The term "o-tolidine" refers to various physical forms of the compound and 
its salts. Synonyms for o-tolidine include 3,3-dimethylbenzidine, 4,4-
diamino-3,3-dimethylbiphenyl, diorthotoluidine, diaminoditolyl, azoic diazo 
reagent, gold diazo reagent, nitro coupling reagent, direct blue 63, fast blue 
R base, and benzo fast blue R. "Occupational exposure to o-tolidine" is 
defined as work in any place in which o-tolidine is produced, stored, used, 
packaged, or distributed. If o-tolidine is handled or stored only in intact, 
sealed containers, (eg, during shipment), adherence to the following sections, 
except for Sections 3, 5(a), 6(g), and 8(a), is not required. This
recommended standard does not apply to users of test tapes or test kits 
containing o-tolidine. Employees shall avoid skin contact with o-tolidine, 
since skin absorption can be a significant source of exposure.
Section 1 - Environmental (Workplace Air)
(a) Concentration
Occupational exposure to o-tolidine shall be controlled so that employees 
are not exposed at a concentration greater than 20 micrograms per cubic meter 
of air (/izg/cu m) , determined as a ceiling concentration in a 1-hour sampling 
period. Skin contact with o-tolidine shall be avoided.
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(b) Sampling and Analysis
Procedures for the collection and analysis of environmental samples shall 
be as provided in Appendix I or by any methods shown to be at least equivalent 
in precision, accuracy, and sensitivity to the methods specified.
Section 2 - Medical
Medical surveillance shall be made available as outlined below to all 
employees occupationally exposed to o-tolidine.
(a) Preplacement medical examinations shall include at least:
(1) Comprehensive medical and work histories with special emphasis 
directed towards the urinary tract.
(2) Comprehensive physical examination to include urinalysis with a 
microscopic examination of cells in urine. If the urinalysis is judged to be 
abnormal, a reexamination shall be performed. If the abnormal finding is 
confirmed, a comprehensive urologic evaluation should follow.
(3) A judgment of the worker's ability to use positive pressure 
respirators.
(b) Periodic examinations shall be made available at least annually to 
employees occupationally exposed to o-tolidine. Quarterly urine examinations 
are recommended. These examinations shall include at least:
(1) Interim medical and work histories.
(2) Comprehensive physical examination as described in (a) (2).
(c) Pertinent medical records shall be maintained for all employees 
exposed to o-tolidine in the workplace. Such records shall be kept for at 
least 30 years after the last occupational exposure to o-tolidine. Records of 
environmental exposures applicable to an employee shall be included in the 
employee's medical records. These records shall be made available to the 
designated medical representatives of the Secretary of Health, Education, and 
Welfare, of the Secretary of Labor, of the employer, and of the employee or 
former employee.
Section 3 - Labeling and Posting
All warning signs shall be printed both in English and in the predominant 
language of non-English-reading employees. Workers who cannot read the 
language used on labels or warning signs shall receive information regarding 
hazardous areas and shall be informed of the instructions printed on labels 
and signs.
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All containers of o-tolidine shall be labeled and all areas where o- 
tolidine is stored, handled, used, produced, or distributed shall be posted in 
accordance with the following subsections.
(a) Containers of o-tolidine shall bear the following label in addition 




CANCER SUSPECT AGENT 
CAN BE ABSORBED THROUGH SKIN
Use only with adequate ventilation.
Handle with gloves resistant to o-tolidine.
Wash from skin immediately.
(b) The following warning sign shall be posted in readily visible 
locations at or near entrances to areas in which o-tolidine is stored, 
handled, used, produced, or distributed:
WARNING— HAZARDOUS AREA 
O-TOLIDINE 
CANCER SUSPECT AGENT 
CAN BE ABSORBED THROUGH SKIN 
AUTHORIZED PERSONNEL ONLY
Section 4 - Personal Protective Equipment and Clothing
Employers shall use engineering controls and safe work practices to keep 
exposure to o-tolidine as low as possible and to minimize skin contact. When 
necessary, these shall be supplemented by the use of personal protective 
equipment. All employees entering the regulated area shall be equipped with 
clean work clothing (long-sleeved shirts, trousers, underwear, and footwear) 
and with the necessary protective equipment. Full-body protection with 
appropriate head covering and air supply shall be used in weighing and
charging operations in which there is occupational exposure to o-tolidine. At
no time shall protective equipment be stored in the regulated area.
(a) Respirators may be used only:
(1) During the time necessary to install and test the required 
engineering controls.
(2) During nonroutine operations or maintenance and repair
activities in which brief exposure to o-tolidine dust or vapor may occur.
3
(b) Respirators permitted or required by paragraph (a) of this section 
shall be supplied-air or self-contained positive-pressure respirators with 
full facepiece and shall comply with the standards jointly approved by NIOSH 
and the Mining Safety and Health Administration as specified in 30 CFR 11. 
All respiratory protective devices should be worn with full-body clothing 
resistant to penetration by o-tolidine. Employers shall provide respiratory 
protection for employees and shall establish and enforce a respiratory 
protection program meeting the requirements of 29 CFR 1910.134 and shall 
ensure that employees use the respiratory protective equipment when necessary.
(c) Employers shall ensure that respirators are properly cleaned and 
maintained. They shall also ensure that employees know the location of 
respirators assigned to them, how to use them, and how to test respirators for 
leaks, proper operation, and proper fit.
(d) Respirators shall be easily accessible. If respirators for more than 
one purpose are present, employees shall be taught to recognize the proper 
one.
Section 5 - Informing Employees of Hazards from o-Tolidine
(a) Employees who work in areas in which o-tolidine is stored, handled, 
used, produced, or distributed shall be informed at the beginning of their 
assignment and at least annually thereafter of the hazards of exposure to o- 
tolidine, including the information that o-tolidine is believed capable of 
causing cancer, that it can be absorbed through the skin, mouth, and 
respiratory tract, and that it may cause kidney damage. Employees shall also
be informed of the value of continued periodic medical examinations.
Information shall also be provided on the specific nature of the operation
that could result in exposure and on how to recognize and evaluate conditions
and situations that may result in the release of o-tolidine. The employer 
shall also inform the employees about cleanup, decontamination, and emergency 
procedures and their role in these activities. Employers shall post this 
information in the workplace and shall keep it on file, readily accessible to 
employees.
(b) Employers shall institute a continuing education program, conducted 
at least annually by persons qualified by experience or training, for 
employees whose jobs may involve occupational exposure to o-tolidine to ensure 
that all such employees have current knowledge of job hazards; relevant 
maintenance, cleanup, and decontamination methods; and proper respirator use. 
The instruction program shall include a description of the environmental and 
medical surveillance procedures and of the advantages to the employee of 
participating in these procedures. As a minimum, instruction shall include 
the information in Appendix III.
(c) Required information shall be recorded on the "Material Safety Data 
Sheet" shown in Appendix III or on a similar form approved by the Occupational
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Safety and Health Administration, US Department of Labor, and kept on file, 
readily accessible to employees at all places of employment where there is 
occupational exposure to o-tolidine.
Section 6 - Work Practices
(a) Emergency Procedures
For all work areas in which emergencies involving o-tolidine may occur, 
employers shall ensure that employees are properly trained and follow the 
procedures specified below and any others appropriate for the specific 
operation or process.
(1) All employees involved in the emergency who may have had skin 
contact with o-tolidine shall wash affected parts promptly and thoroughly.
(2) Persons essential to emergency operations shall have the
approved protective clothing and respirators, as specified in Section 4, 
readily available.
(3) Procedures shall be prepared for maintenance or cleanup and 
decontamination of areas where leaks or discharges of o-tolidine have
occurred. Employees not essential to emergency operations shall be evacuated 
from the affected areas during emergencies. Perimeters of these areas shall 
be delineated, posted, and secured.
(4) Only personnel properly trained in emergency procedures and 
protected against the attendant hazards shall clean up and decontaminate 
spills and control and repair leaks. After cleanup and decontamination,
protective clothing and equipment shall be decontaminated and removed and the
employee required to shower.
(5) Emergency telephone numbers shall be prominently posted.
(b) Engineering Controls
Engineering controls shall be used to prevent the inhalation of, and to 
minimize skin contact with, o-tolidine by controlling the amount of o-tolidine 
that is emitted into the air and, indirectly, the amount present in the work 
area through settling. The most effective control measure is enclosure of 
unit operations and processes. For small operations, glove boxes or 
laboratory hoods may constitute sufficient enclosure. Local exhaust 
ventilation may also be effective when used at the source of o-tolidine 
emission.
Ventilation systems shall be inspected for corrosion, subjected to regular 
preventive maintenance, and cleaned at least every 6 months to ensure their 
effectiveness. The effectiveness of the system shall be verified by airflow 
measurement at least annually and a log showing the results of annual
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inspections shall be kept. Exhaust ventilation systems shall discharge to the 
outside air through an appropriate filtering device and shall conform to 
applicable local, state, and Federal regulations. Contaminated exhaust air 
shall not be recirculated or discharged to other work areas, either regulated 
or unregulated.
Enclosures, exhaust hoods, and ductwork shall have pressure-failure alarms 
and shall be kept in good repair so that design airflows are maintained. 
Airflow at each hood shall be measured at least quarterly, but monthly 
measurements are recommended. Continuous airflow indicators, such as water or 
oil manometers properly mounted at the juncture of fume hood and duct throat 
(marked to indicate acceptable airflow), are recommended. A log showing 
design airflow and the results of quarterly inspections shall be kept and may 
be used in place of the annual inspection log of the ventilation system.
(c) Regulated Areas
Regulated areas shall be established and maintained where o-tolidine is 
manufactured, used, processed, or repackaged. Access to these areas shall be 
limited to authorized persons. This requirement for regulated areas includes 
the manufacturing and processing of o-tolidine test tapes and test kits, but 
it does not apply to the use of such tapes or kits for testing applications 
(such as for water analysis for chlorine or for measurement of occult blood) 
if skin contact with o-tolidine is avoided. An entry roster shall be kept of 
employees entering regulated areas. Toilets shall be located in regulated 
areas for use of employees in these areas and shall be separate from other 
toilet facilities.
(1) Access to the regulated area shall be limited to employees 
having assigned duties there.
(2) A daily entry roster shall be kept of all employees entering the 
regulated area and of their length of stay.
(3) Employees working in regulated areas shall wash their face, 
neck, hands, and forearms each time they leave the regulated area. Washing 
facilities shall be provided at each exit. Employees working in regulated 
areas shall wash their hands and forearms before and after using the toilet.
(4) Employees engaged in operations in which o-tolidine is 
transferred, charged, or discharged, or which involve using a laboratory-type 
hood, opening a closed system, or repackaging, shall be provided with gloves 
and aprons or coveralls or with full-body protective suits resistant to 
penetration by o-tolidine.
(5) As a backup precaution, employees using glove boxes to handle o- 
tolidine shall wash their hands and arms on completion of the assigned task.
(6) When employees use protective clothing and equipment, they shall 
remove it and leave it at the exit before they leave the regulated area; the
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employees shall then wash their hands, forearms, face, and neck to remove 
accumulated o-tolidine before they enter nonregulated areas.
(d) Clean Room
A clean room shall be established and maintained that is free of o- 
tolidine contamination and that contains locker facilities.
(1) Shower facilities shall separate the clean room from the 
regulated area.
(2) The clean room shall be kept under positive pressure relative to 
the regulated area.
(3) Signs meeting the requirements of Section 3 shall be posted at 
the doorway separating the clean room and regulated area. Instructions 
informing employees of the procedures for entering and leaving the regulated 
area shall also be posted.
(4) Employees assigned to the regulated area shall change into clean 
work clothing (long-sleeved shirts, trousers, underwear, and footwear) each 
day before entering the regulated area. The necessary protective clothing and
equipment shall also be put on at this time.
(5) At the end of each workday, protective clothing, work clothing, 
and protective equipment shall be removed and placed in clearly labeled 
containers located in the regulated area. The employee shall then proceed to
the shower facility and shower and shampoo before entering the clean room to
put on street clothing.
(e) Decontamination
Good housekeeping practices shall be observed to prevent contamination of 
areas and equipment with o-tolidine solids, solutions, and aerosols. The 
regulated area shall be washed thoroughly at the end of each shift to prevent 
such contamination.
Solids or solutions containing o-tolidine shall be removed from work areas 
by vacuum cleaning with a specially designated vacuum cleaner or by other 
methods, including wet methods, that do not increase the concentration of 
airborne o-tolidine. No dry sweeping, blowing by compressed air, or any 
method of dust removal that increases the concentration of airborne o-tolidine 
shall be allowed. After cleanup, the area shall be decontaminated and washed 
with water.
(f) Laundering
The employer shall provide for the daily decontamination and laundering of 
used work clothing. Clothing should be washed with soap or other detergent 
and water. Precautions shall be taken to protect personnel who handle and
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launder soiled clothing. These employees shall be advised of the hazards of, 
and means of preventing, exposure to o-tolidine. If an outside laundry 
facility is used, the launderers shall be advised of the hazards and proper 
procedures involved in handling contaminated work clothing. Contaminated 
clothing that is to be transported to an outside laundry facility shall be 
placed in sealed containers.
(g) Storage
Storage areas shall be isolated, well ventilated, and fire-resistant. 
Containers of o-tolidine shall be tightly closed and stored safely away from 
strong oxidizing materials and corrosive liquids and gases, heat, explosives, 
and gases under pressure to minimize the possibility of accidental breakage or 
spills.
(h) Maintenance
Lines and fittings that may carry o-tolidine shall be made of materials
resistant to penetration of o-tolidine and shall be inspected frequently for
corrosion and leaks. All o-tolidine equipment, including valves, fittings, 
and connections, shall be checked for tightness and kept in good working 
order. Such inspections shall be made immediately after new connections are 
made and after o-tolidine is introduced. Repairs and adjustments shall be 
made promptly.
(i) Entry into Confined Spaces
Entry into confined spaces, such as tanks, pits, and process vessels, that 
have contained o-tolidine shall be controlled by a permit system. Permits 
shall be signed by an authorized employer representative, certifying that 
preparation of the confined space, precautionary measures, and personal
protective equipment are adequate and that prescribed procedures will be 
followed.
(1) All lines shall be disconnected or blocked while a vessel is 
being cleaned. All valves or pumps leading to and from the vessel shall be 
locked out or tagged out.
(2) The vessel shall be either washed with water and purged with air 
or purged with nitrogen and then with air.
(3) The vessel shall then be checked by trained personnel for fire
or explosion hazard, airborne o-tolidine, possible oxygen deficiency, and
concentrations of other likely contaminants, to assure that no danger exists.
(4) If a respirator is necessary, a self-contained breathing
apparatus as specified in Section 4 of this chapter shall be provided to the 
employee.
(5) Each employee entering the vessel shall be equipped with
appropriate respiratory protection, a harness, and a lifeline. At least one
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other person equipped with appropriate respiratory protection, harness, and 
lifeline shall watch at all times from the outside. At least one more person 
shall be available to assist in an emergency. Mechanical ventilation shall be 
provided continuously when workers are inside the vessel.
(j) Disposal
Waste material contaminated with o-tolidine and containers of o-tolidine 
shall be disposed of in a manner not hazardous to employees. The disposal 
method shall conform to applicable local, state, and Federal regulations and 
shall not constitute a hazard to the surrounding population or environment. 
Waste water shall be flushed to holding basins for decontamination.
Section 7 - Sanitation
(a) The pertinent requirements for plant sanitation, stated in 29 CFR 
1910.141, shall be complied with. The subsections entitled General (a), 
Toilet Facilities (c), Washing Facilities (d), Change Rooms (e), and 
Consumption of Food and Beverages on the Premises (g) are especially relevant 
to o-tolidine.
(b) Washing facilities, conveniently located and near the exit, shall be 
provided to employees in the regulated area. Locker room facilities, 
including showers, shall be located outside the regulated area.
(c) Preparing, storing, dispensing (including that done through vending 
machines), or eating food shall be prohibited in regulated areas.
(d) Smoking shall be prohibited in regulated areas.
Section 8 - Monitoring and Recordkeeping Requirements
(a) Industrial Hygiene Surveys
Each employer who has a place of employment in which o-tolidine is stored, 
produced, processed, or otherwise handled shall determine by an industrial 
hygiene survey the areas in which occupational exposure to o-tolidine occurs. 
Records of these surveys shall be retained until the next survey has been 
completed. For areas where an employer concludes that there is no 
occupational exposure to o-tolidine, the records shall show the basis for 
this conclusion. Surveys shall be repeated at least annually and within 14 
days after any process change likely to result in occupational exposure to o- 
tolidine.
(b) Personal Monitoring
If it has been determined that occupational exposure to o-tolidine occurs, 
the employer shall institute environmental monitoring.
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(1) A program of personal monitoring shall be instituted to identify
and measure, or permit calculation of, the exposure of each employee. Source
and area monitoring may be used to supplement personal monitoring.
(2) In all personal monitoring, samples representative of exposure
in the breathing zone of the employee shall be collected.
(3) For each determination of the concentration of o-tolidine, a 
sufficient number of samples shall be taken to characterize the employee's 
work and production schedules, location, or duties, and changes in production 
schedules shall be considered in deciding^when samples are to be collected.
(4) Each operation in each regulated area shall be sampled at least 
once every 6 months while o-tolidine is produced or handled. For intermittent 
operations, ie, those lasting less than 6 months, at least one monitoring 
regimen shall be conducted during each operation period and monitoring should 
coincide with the periods of maximum potential exposure to o-tolidine during 
these intermittent operations.
If an employee is found to be exposed to o-tolidine at concentrations 
exceeding the recommended ceiling limit, the exposure of that employee shall 
be measured at least once every week, control measures shall be initiated, and 
the employee shall be notified of the exposure and of the control measures 
being implemented. Such monitoring shall continue until two consecutive 
determinations, at least 1 week apart, indicate that control measures are 
effective in that the employee's exposure no longer exceeds the recommended 
occupational exposure limit; routine semiannual monitoring may then be
resumed.
(c) Recordkeeping
Records of environmental monitoring and other pertinent records shall be 
kept for at least 30 years after the employee's last occupational exposure to 
the o-tolidine. Records of environmental monitoring shall include an 
identification of the employee being monitored, duties and job locations
within the worksite, time and dates of sampling and analysis, sampling and 
analytical methods used and available evidence of their precision and
accuracy, the number, duration, and results of samples taken, environmental 
concentrations determined from these samples, and the type of personal 
protective equipment used by the employee. Entry rosters of authorized 
persons who enter regulated areas shall also be retained for at least 30 
years. Environmental monitoring records and entry rosters shall be made 
available to designated representatives of the Secretary of Labor and of the 
Secretary of Health, Education, and Welfare. Employees shall have access to 
data on their environmental exposures. Medical records shall be made
available to the designated medical representatives of the Secretary of Labor, 
of the Secretary of Health, Education, and Welfare, of the employer, and of 
the employee or former employee.
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II. INTRODUCTION
This report presents the criteria and the recommended standard based 
thereon that were prepared to meet the need for preventing disease or injury 
arising from occupational exposure to o-tolidine. The criteria document 
fulfills the responsibility of the Secretary of Health, Education, and Welfare 
under Section 20(a)(3) of the Occupational Safety and Health Act of 1970 to 
"develop criteria dealing with toxic materials and harmful physical agents and 
substances which will describe...exposure levels at which no employee will 
suffer impaired health or functiogal capacities or diminished life expectancy 
as a result of his work experience."
After reviewing data and consulting with others, NIOSH formalized a system 
for the development of criteria on which standards can be established to 
protect the health and to provide for the safety of workers from exposure to 
hazardous chemical and physical agents. The criteria and recommended standard 
should enable management and labor to develop better engineering controls and 
more healthful work practices, and simply complying with the recommended 
standard should not be the final goal.
These criteria for a standard for o-tolidine are part of a continuing 
series of criteria developed by NIOSH. The proposed standard applies to the 
processing, manufacture, storage, handling, and use of o-tolidine. The 
standard was not designed for the population-at-large, and any extrapolation 
beyond occupational exposures is not warranted. It is intended to protect 
against injury to health from o-tolidine, be measurable by techniques that are 
valid, reproducible, and available to industry and governmental agencies, and 
be attainable with existing technology.
o-Tolidine is widely used in small quantities in chromatography and other 
analytical chemistry techniques, including water test kits for chlorine, and 
in biologic stains. It has been used as a direct dye for textiles but is most
commonly used as an intermediate from which other dyes are made. It may be
used as a precursor or as a curing agent in the manufacture of urethane
resins. The use of o-tolidine in the United States is expected to decline.
Absorption of o-tolidine through the intact skin and from the respiratory 
and gastrointestinal tracts has been reported. Cancer and kidney damage have 
been reported in animals exposed to o-tolidine alone at high doses. Bacterial 
tests of mutagenicity and mammalian tests of DNA damage further support the 
findings of mammalian carcinogenicity. Furthermore, o-tolidine resembles 
benzidine, a known human carcinogen, in chemical structure, physical 
properties, and metabolism and excretion. o-Tolidine is, therefore, judged to 
pose a risk of cancer in workers. The recommended standard for occupational 
exposure to o-tolidine is based on keeping exposure at the lowest possible 
level through engineering controls and work practices. The recommended 
sampling and analytical methods have been evaluated for benzidine and are 
expected to be useful for o-tolidine.
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The development of the recommended standard for occupational exposure to 
o-tolidine has revealed the need for additional data in several areas, 
especially on the effects of long-term occupational exposure to o-tolidine in 
the absence of other aromatic amines, possible carcinogenic, teratogenic, or 
mutagenic effects, and possible kidney damage.
%
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III. BIOLOGIC EFFECTS OF EXPOSURE
o-Tolidine is a symmetrical biphenyl compound with an amine group and a 
methyl group attached to each ring. The amine groups are in the para position 
to the biphenyl link; the methyl groups are in the ortho position to the amine 
group [1,2]. The structures of several biphenyl amines, including o-tolidine 
and benzidine, are similar. These substances are sometimes called biphenyl 
amines, aminobiphenyl compounds, or simply diamines. Because they have been 
measured colorimetrically by the formation of colored holoquinone complexes
[3], aminobiphenyl compounds have also been referred to as quinonizable 
substances. Their physical and chemical properties are also similar [1,2], 
For example, o-tolidine melts at 129 C, is slightly soluble in water, and is 
soluble in alcohol and ether, whereas benzidine has a melting point of 126 C, 
is slightly soluble in water and alcohol, and is soluble in ether. The 
chemical structures of some aromatic amine compounds are given in Figure III-l 
[4,5].
Extent of Exposure
o-Tolidine (3,3'-dimethyl,4,4'-diamino biphenyl, formula weight 212.32) is 
a crystalline solid. Salient physical and chemical properties of o-tolidine 
and benzidine are listed in Table XII-1 [1,2,5,6]. o-Tolidine is used both as 
a dye and as an intermediate in the production of other dyes [4] . It is 
widely used in small quantities as a laboratory analytical reagent and is a 
moiety of the commonly used biologic stain, trypan blue [7]. o-Tolidine is 
used in small quantities in chlorine test kits by water companies and swimming 
pool owners and in test tapes in clinical laboratories. Although other 
chemicals are preferred, o-tolidine has been used as a curing agent for 
urethane resins, in part because some of the other curing agents, eg, 4,4'- 
methylene bis (2-chloraniline)(MOCA), were proposed for stringent regulation 
as carcinogens (29 CFR 1910.93).
o-Tolidine is prepared from o-nitrotoluene by reduction to a hydrazo 
compound and rearrangement to the biphenyl amine in the same manner that 
benzidine is made from nitrobenzene [4]. Reduction is usually carried out 
with zinc dust and caustic soda in organic solvents [4]. Other reducing 
agents used in the manufacture of o-tolidine may also be used to prepare 
benzidine [4]. If m-nitrotoluene is the starting material, m-tolidine (2,2- 
dimethyl-4,4'-diamino biphenyl) is formed; dyes made from m-tolidine may be 
used for dyeing wool, but they have little affinity for cotton [4].
The major US manufacturer of o-tolidine makes an average of 200,000 pounds 
of o-tolidine salts, eg, hydrochloride, each year. Smaller quantities are 
produced by other companies. US production data on o-tolidine base are not 
available. Many chemical companies buy o-tolidine in bulk from other,
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principally foreign, manufacturers, repackage it, and sell it in smaller 
units; they sometimes refine it. About 300,000 pounds of o-tolidine base and 
150,000 pounds of o-tolidine salts are imported annually [8,9].
Workers potentially exposed to o-tolidine are listed in Table XII-2 [4]. 
Workers exposed to the greatest amounts of o-tolidine are probably dye makers, 
toluene-diisocyanate makers, clinical or analytical chemistry laboratory 
workers, and repackagers [4,10]. Workers in a variety of occuptions may be 
exposed to small quantities of o-tolidine for analytical purposes, among them 
water and sewage plant attendants, sanitarians, forest service chemists, 
swimming pool service representatives, and chemical test tape or kit makers. 
It is estimated that less than 100 employees are exposed to large quantities 
of o-tolidine in the United States, but as many as 200,000 may be exposed to 
small quantities [11].
Historical Reports
In 1932, Berenblum [12] reviewed the incidence of "aniline cancer." The 
term "aniline cancer" was a general term used to refer to bladder cancer 
resulting from exposure to synthetic organic dyes derived from aniline, and to 
other similar dyes. Aniline was originally thought to cause cancer but more 
recently has been held to be noncarcinogenic [13]; use of the term "aniline 
cancer" has since been discontinued [12]. Berenblum concluded that the 
incidence of bladder tumors in dye-industry workers varied in different 
factories, districts, and countries. The data, however, did not point to any 
single reason for this variation. For example, the incidence of bladder 
tumors was higher in Germany than in other countries, even when the values 
were corrected for the greater size and age of the German dye industry. The 
variation in tumor incidence, however, was also found in different factories 
within Germany. It was observed that the incidence of bladder tumors 
decreased in one district after various protective measures were instituted in 
the work practices of these factories. Berenblum [12] suggested that other 
factors, eg, individual susceptibility, age, race, length of exposure, and 
type of industrial process for dye making, contributed to variation in tumor 
incidence.
Berenblum [12] also found reports of tumors localized in other parts of 
the body. Rehn, in 1895, described how one dye worker had carcinomas in the 
right ureter and kidney as well as of the bladder with metastases chiefly in 
the lumbar lymph nodes. Another worker developed a cancer of the renal pelvis 
of a hydronephrotic kidney. The bladder, however, appeared to be by far the 
most frequent tumor location. Both benign and malignant tumors were found, 
the malignant tumors developing as early as the benign tumors. Berenblum 
found suggestions, dating from 1920, that periodic urine testing and 
cystoscopic examinations of workers would aid in early diagnosis of bladder 
tumors.
Until 1932, few experimental studies were conducted to determine which 
individual chemicals in the dye industry were carcinogenic. The results
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reported before then were inconclusive, but it was widely accepted that the 
causative agents were to be found among the many intermediates used to prepare 
the dyes [12].
Scott and Williams [14], in 1957, wrote work practice recommendations for 
the control of bladder cancer caused by occupational exposure. They suggested 
that large amounts of o-tolidine, dianisidine, and dichlorobenzidine should be 
treated like benzidine. Benzidine was by then an accepted human carcinogen 
[13,15].
Effects on Humans
Most investigations regarding o-tolidine have centered on its action on 
the urinary tract, but they have not developed evidence of chronic effects 
attributable solely to o-tolidine exposure. There have also been informal 
comments made to NIOSH regarding nasal irritation. This information is
consistent with the observations of one researcher [16]. No other symptoms
directly referable to o-tolidine were reported.
Brown and coworkers [17] found no o-tolidine in the urine of one human 
volunteer exposed to 100 mg of moistened crystalline o-tolidine for 48 hours. 
It was held against the skin under gauze patches according to the Draize 
technique [18]. They did detect urinary excretion of 0.113 mg of o-tolidine 
after 24 hours when 200 mg was applied to the palm of the hand for 8 hours 
under a rubber glove. No skin irritation was observed.
When one female volunteer was given three oral doses of 100 mg of o-
tolidine (65.1% as base), she excreted 5.60-7.47 mg/day [17]. There were no
quinonizable substances detected in the urine after 3-4 days.
Rye et al [19] mentioned in a review of diamine toxicity that they had
found no cases of human cancer in two decades of experience with workers 
exposed to o-tolidine, dianisidine, and dichlorobenzidine, but specific data 
were not given to support this observation. There were, however, 23 cases of 
urinary system cancer reported in Japanese workers exposed to benzidine, o- 
tolidine, and dianisidine [20]. The length of exposure and the period between 
onset of exposure and the development of tumors were not reported, except that 
14 workers (61%) had been exposed less than 6 years.
Macalpine [21] described two cases of papilloma of the renal pelvis in
workers manufacturing o-tolidine and benzidine. Other chemicals occasionally 
handled included azobenzol, nitrobenzol, and o-nitrotoluol. The first 
worker's urine contained red blood cells, and a red, coarsely nodular 
papilloma was discovered in the vault of the bladder by cystoscopy. It was 
not necrotic. A smaller papilloma with fronds was located on the left wall of 
the bladder near the urethra. The man was treated by diathermy, and nine 
cystoscopic examinations over the next 3.5 years showed him to be tumor free. 
He then complained of difficulty in urinating, although there was no 
hematuria. Papillomas found at the neck of the bladder were treated by
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diathermy. Several months later, the bladder tumors had grown larger and a 
large mass was felt in the area of the left kidney. The enlarged left kidney 
and ureter were removed surgically, and the bladder was treated by diathermy. 
The patient was discharged, but he was readmitted within 4 months with 
hematuria. Papillomas were found again at the neck of the bladder; they were 
larger than before and treated by surgery and diathermy. The patient died 
suddenly of hemorrhage during the course of treatment; no autopsy was 
permitted.
The second worker described by Macalpine [21] had a similar occupational 
and medical history. Eight cystoscopic examinations in 3.5 years were 
negative, then papillomas recurred in the kidney while the bladder remained 
free of tumors. He experienced recurrent anuria and died of uremia. At 
autopsy both kidneys were found to be affected. The right kidney was greatly 
enlarged by a papillary carcinoma. The left kidney cortex had atrophied; a 
papilloma obstructed part of the upper calyx. The bladder and both ureters 
appeared normal. The effects attributable to benzidine could not be 
distinguished from those of tolidine, and the isomer of tolidine was not 
identified. This report suggests the need for comprehensive urologic 
evaluation, including kidney function tests and microscopic examination for 
red blood cells and abnormal epithelial cells in urine. Repeated cystoscopy 
did not detect tumors in the upper part of the urinary tract.
In Italy, Barsotti and Vigliani [13] collected data on bladder lesions in 
200 workers in the dye industry. Exposure to o-tolidine may have occurred but 
was not mentioned specifically. The workers had received routine cystoscopic 
examinations between 1931 and 1948. The authors found that beta-naphthylamine 
and benzidine were the most dangerous carcinogens of the aromatic amines to 
which the workers were exposed, whereas aniline had no appreciable 
carcinogenic potential. Tumors appeared 4-28 years after initial contact with 
beta-naphthylamine or benzidine.
In 1954, Meigs et al [22] analyzed urine samples from workers over a 5- 
year period at a plant manufacturing benzidine, dichlorobenzidine, 
dianisidine, and o-tolidine. About 900 samples from production workers and 
about 250 samples from non-production controls located in the same building 
were analyzed by the chloramine-T test. In addition, 17 control urine 
specimens were obtained from an employee in a different building 500 yards 
away, and 35 control specimens were obtained from men and women working in a 
nearby university and hospital. The number of individuals participating was 
not stated. Workers were required to shower daily after the workshift and 
provide a clean urine specimen. Air samples from production areas contained 
"quinonizable" (holoquinone-forming) substances at concentrations of 2-87 
y.g/cu m, with a mean of 18 ±2 ¿ig/cu m. Air from other areas in the same 
building contained less than 1 Mg/cu m. The chloramine-T test did not 
distinguish among aminobiphenyl compounds; separation was accomplished by 
paper chromatography. The results were generally reported in units of 
benzidine.
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Urine samples from workers producing benzidine and substituted benzidines 
contained quinonizable substances in mean concentrations of 144-1,482 jug/liter 
and averaged about 500 jug/liter [22]. Samples from workers not making 
benzidine and related amines contained less than 15 /¿g/liter of quinonizable 
substances. Specimens from a worker in another building had a mean of 6 
jug/liter, and the control samples from the university and hospital workers 
contained no detectable biphenyl diamines. Urine specimens from foremen had 
lower biphenyl diamine concentrations than did those from workers who actually 
handled the substances. Operators who were directly exposed excreted about 
500 /ug/liter of o-tolidine and foremen excreted about 50 /ug/liter. Biphenyl 
diamine concentrations in urine were lower in the winter and higher in the 
summer, although the specific gravity of the urine did not differ appreciably. 
Higher concentrations of excreted biphenyl diamines were also associated with 
higher humidity. This is consistent with Meigs' speculation that increased 
skin moisture from sweating increased diamine absorption. A downward trend 
was noted in urinary excretion of biphenyl diamines over 3 years. The summer 
mean declined from 1,482 to 570 jug/liter, the winter mean from 433 to 144 
/ig/liter. This decrease was related to improved work practices and personal 
hygiene.
Brief but heavy exposure to a substituted benzidine resulted in a 1-day 
elevation of excreted quinonizable substance [22] . A worker was accidentally 
drenched with a slurry containing dichlorobenzidine hydrochloride in acid 
solution. Although he took a shower and changed his clothes within 5 minutes 
of the accident, his urinary excretion of diamines went from 43 to 1,130 
jug/liter for 1 day and then returned to baseline levels.
Results of urinalyses from other workers led to the discovery of 
previously unrecognized sources of exposure, such as contaminated boots or 
gloves [22]. One worker had made only o-tolidine, dianisidine, and 
dichlorobenzidine, but chromatographic analysis of his urine sample for that 
day showed benzidine as well as the three diamines to which he was known to 
have been exposed. Investigation revealed that his boots were contaminated 
with benzidine. Similarly, o-tolidine was found in urine samples of two 
workers who had made only dichlorobenzidine on the day in question and in 
another sample from a worker who had that day made only m-aminophenol.
When both the skin and the clothing were carefully decontaminated, the 
urinary concentrations of biphenyl amines decreased markedly [22]. Before the 
initiation of a personal hygiene program at the workplace, one worker's 
specimens contained quinonizable substances in concentrations averaging 117 
jug/liter, the concentration tending to increase slightly as the week
progressed. After hygienic work practices were adopted, his average urinary 
output of quinonizable substances had fallen 80%, to 21 jug/liter, at the end 
of 14 months [22].
The authors [22] concluded that absorption of aminobiphenyl compounds, 
such as o-tolidine, through the skin was a more important hazard than was 
inhalation of airborne particles of these compounds. They based this
conclusion on several observations. First, the concentrations of the
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compounds in the workplace air were too low to produce the reported urinary 
concentrations. Also, foremen in the production areas excreted very little 
quinonizable substance compared with the workers actually handling the 
substances in the same areas, and the substances excreted corresponded to the 
substances to which the workers were exposed. Because diamine excretion 
increased with larger exposures (splashes) and on hot, humid days, Meigs et al 
suggested that moist skin was conducive to absorption of benzidine and 
substituted benzidines. They suggested that producing substituted benzidines 
in the winter or in air-conditioned facilities would reduce absorption through 
the skin by keeping the skin dry. It should be noted again that the 
chloramine-T test is not specific and that positive results were followed up 
by separation by paper chromatography. Whether this detection of unexpected 
diamines may have been the result of mixed exposures, chromatographic error, 
or biotransformation is not clear, but the latter is hard to demonstrate. The 
explanation offered by Meigs et al, that there were occult exposures to other 
chemicals deposited in boots or clothing, is the most probable. When this 
study was performed in the early 1950's, skin contact was generally considered 
the greatest hazard. With the subsequent improvement of engineering controls 
and work practices, skin contact with o-tolidine could be effectively 
controlled, and concern shifted to the inhalation hazard of airborne o- 
tolidine.
A study of occupational bladder tumors in the Japanese dye industry, by 
Tsuchiya et al [23] in 1975, reported that 1 worker of 107 exposed to "other 
amines, e.g. orthotolidine, including mixed exposures," excluding benzidine 
and alpha- and beta-naphthylamine, had a positive urinary Papanicolaou test. 
The workers' ages and the type and extent of exposure were not reported. Beth 
active and retired workers were tested. Probably all workers exposed to o- 
tolidine are also exposed to other amines that may be carcinogenic.
Animal Toxicity
While experimental evidence of the effects of exposure to o-tolidine is 
meager, a few animal studies have attempted to elucidate the toxicologic 
properties of o-tolidine.
(a) General
Rye et al [19] stated in a review of diamine toxicity that o-tolidine base 
penetrates the skin more readily than its salts, but no supporting data were 
given.
In studies of acute toxicity in various species of animals, the toxicity 
of o-tolidine appears to be similar to, perhaps slightly greater than, that of 
benzidine. In the rat, the oral LD50 of o-tolidine was 404 mg/kg [24]; for 
benzidine, it was 566 mg/kg [25]. LD50's of 90.9 mg/kg and 199.4 mg/kg for o- 
tolidine and benzidine, respectively, were determined after albino mice were 
given intraperitoneal (ip) injections [17] . Renal toxicity of o-tolidine from 
a single dose administered orally to the rabbit was said to be greater than
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that of benzidine [16], but no quantitative comparison was made.
In 1908, Adler [16] reported that three rabbits weighing about 2 kg each 
were given o-tolidine suspended in water orally at a daily dose of 1 g. The 
results, anuria, lethargy, and death within a few days, were said to be 
similar in all three rabbits tested. According to Adler, effects which he 
termed "urinary excretion disorders" were produced in rabbits by o-tolidine 
but not by benzidine.
Brown et al [17] evaluated skin irritation in six albino rabbits. The fur 
was clipped close to the skin and 0.5 g of o-tolidine, 65.1% base and the rest 
dihydrochloride, was kept on the skin under small gauze patches for 24 hours. 
No irritation was noted with intact skin, but very slight erythema appeared 
when o-tolidine was applied to abraded skin. This suggests that any cutaneous 
absorption of o-tolidine will probably not be accompanied by significant 
irritation; thus, it might not be noticeable.
Maruya [26] fed o-tolidine, at a 5% concentration in olive oil, mixed with 
rice at 20 cc of olive oil solution/kg of rice, to nine adult albino rats for 
21-111 days. Control rats were not reported, but a total of 311 other rats 
were administered 4 other aromatic amines or 14 azo pigments. The ratio of 
males to females in each group was not reported, but half of the total of 320 
rats were male. The kidneys of each rat were microscopically examined when 
the animal died during, or was killed at the end of, the experiment. Six of 
the rats exposed to o-tolidine had swelling and thickening of the cells lining 
the uriniferous tubules (two mild, two moderate, and two severe), with an 
accumulation of giant cells with abnormally large nuclei in the distal 
straight portions. The tubular lumen was narrowed. Two other rats showed a 
mild accumulation of pigment derived from hemolysis in the tubular epithelial 
cells. The degeneration of tubular cells was generally more severe when 
pigment granules were found in the cells, but it was not stated whether this 
finding occurred in rats fed o-tolidine. No results were reported for the 
ninth rat given o-tolidine. Maruya considered it significant that chemicals 
like o-tolidine, with a slight tendency to induce hemolysis and pigmentation 
of the uriniferous tubule cells, strongly provoked swelling of the tubular 
epithelium and massing of giant cells with heteromorphous giant nuclei.
(b) Carcinogenesis, Mutagenesis, and Teratogenesis
Early attempts to induce tumors of the urinary system experimentally by 
injecting animals with suspensions of o-tolidine at an unreported dose for 18 
months did not succeed [27] . Feeding o-tolidine to dogs similarly yielded no 
bladder tumors [28] . In an experiment performed by Brown and Franz and 
reported by Ferber [29] , there was one case of bladder cancer in dogs fed o- 
tolidine. In a brief commentary on the use of hamsters in studying induction 
of bladder cancer by aromatic amines, Saffiotti and colleagues [30] said they 
found no carcinogenic activity in hamsters fed o-tolidine (or 2-naphthylamine 
or benzidine as well as some other aromatic amines) at 0.1% in the diet. No 
supportive details were given.
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Experiments, primarily on dogs, were reported in 1948 by Gehrmann and 
colleagues [28] . The following compounds were fed to dogs in daily doses 5 
times a week for the time period indicated: aniline (300 mg/3.5 years),
benzidine (117 mg/5 years), dianisidine (291 mg/3.5 years), alpha-
naphthylamine (technical, 330 mg/4.5 years), alpha-naphthylamine (pure, 301
mg/4.5 years), phenyl-alpha-naphthylamine (290 mg/3 years), phenyl-beta- 
naphthylamine (540 mg/4.5 years), tolidine (isomer not specified, 230 mg/3
years), and beta-naphthylamine (300 mg/50 days). Only beta-naphthylamine was 
found to produce bladder tumors. No bladder tumors were induced in the three 
female dogs fed tolidine. The total dosage of tolidine was almost 180 g. 
Benzidine did not induce detectable bladder tumors or papillomas in these 
dogs.
As previously mentioned, Ferber [29], in 1970, prepared an unpublished 
report of an experiment designed to indicate whether bladder cancer could be 
induced by o-tolidine in dogs and whether it would continue to develop after a 
normal diet was resumed. Four young mongrel bitches weighing 40-48 pounds 
(18-22 kg) each were given 200 mg of o-tolidine in gelatin capsules daily for 
8-9 months, a total dose of almost 50 g per dog. The findings of cystoscopic 
examinations before and after o-tolidine administration were negative. One 
dog died of bladder cancer (papillary tumor and cystitis) 8 years after the 
last cystoscopic examination. Another dog died of natural causes soon after 
the first, but no tumors were found at autopsy. The last two dogs were then 
killed and examined, but no tumors were found. Ferber concluded that o- 
tolidine may be a weak carcinogen but is not as carcinogenic as benzidine. 
This conclusion could not be supported statistically, because too few dogs 
were studied. Old dogs may develop tumors spontaneously; however, bladder 
tumors in dogs are rare [31].
Spitz et al [15], in 1950, reported the carcinogenic potential of 
benzidine. Clinical evidence had been lacking until then, because workers 
exposed to benzidine had frequently also been exposed to beta-naphthylamine, a 
recognized carcinogen [15]. The experiments of Spitz et al on rats dealt with 
the individual effects of benzidine; other compounds encountered during its 
manufacture, such as azoxybenzene, hydrazobenzene, and benzidine sulfate; and 
those closely allied to it chemically, such as tolidine, azobenzene, and 
benzidine disulfonic acid. All chemicals were injected subcutaneously (sc). 
Benzidine sulfate was also fed to rats. Results showed that benzidine did not 
produce bladder cancer in rats, but it did produce hepatomas and tumors of the 
Zymbal glands (the specialized sebaceous glands of the rat's auditory canal). 
o-Tolidine also produced tumors of the Zymbal glands. Technical grade 
benzidine caused more tumors than pure benzidine; however, the reason for this 
difference was not discussed. o-Tolidine caused fewer tumors in spite of 
injection of four times more o-tolidine (60 mg) than benzidine (15 mg) each 
week, suggesting that o-tolidine is a less potent carcinogen than benzidine. 
Fifty control rats did not develop tumors.
Holland et al [32] administered o-tolidine sc in peanut oil to 21 Alderly 
Park strain rats for 241 days (cumulative dose, 5.4 g/kg). The rats survived 
94-703 days following the first dose of o-tolidine; tumors were not detected
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at necropsy until day 325. A total of 18 rats developed tumors, including 
tumors of the gastrointestinal tract (11), hepatomas (7), tumors of the bone 
and associated tissues (including hematopoietic tissues) (4), and Zymbal gland 
tumors (40. Similarly, 22 rats were administered benzidine sc for 150 days 
(cumulative dose, 0.75 g/kg). Treated rats survided for 24-387 days following 
the first dose of benzidine. Tumors were not detected at necropsy until day 
84 as compared with day 325 for o-tolidine. A total of 20 of 22 rats 
developed tumors (compared with 18/21 for o-tolidine), notably hepatomas (19), 
cholangiomas (18), intestinal tumors (7), and tumors of the Zymbal glands (4).
Holland et al [32] also tested 3,5,3',5'-tetramethylbenzidine in peanut 
oil administered sc to 24 male rats for 32 weeks at doses varying from 100 to
25 mg/kg during the testing period. A control group of 12 rats was given
peanut oil sc only. Gross and microscopic post-mortem examinations revealed a 
few tumors but none that the authors could definitely relate to 3,5,3',5'- 
tetramethylbenzidine. Holland et al regarded the tumors associated with the 
administration of o-tolidine and benzidine as having been induced by these 
chemicals.
In 1970, Pliss and Zabezhinsky [33] reported the results of sc 
administration of o-tolidine to rats either in oil suspension or in glycerin 
pellet implants. The results were also discussed in two other publications 
[34,35]. White rats of both sexes weighing 100-120 g were used in five 
experiments. The only general statement about control animals was that 2.5% 
of an unreported number of untreated old virgin female rats developed 
fibroadenomas of the mammary glands.
In the first experiment, 27 males and 26 females were injected once a week
with 20 mg of o-tolidine in sunflowerseed oil for 13 months [33] . The total 
dose for each rat was 1.16 g. The appearance of tumors was noted, and 
necropsies were ultimately performed on all animals. Tumors and abnormal 
organs were examined microscopically. Tumors appeared in rats of both sexes 
in 8 months; two males and one female died before the appearance of tumors
[33]. Seventeen males and 13 females developed tumors, some more than one 
[33-35]. Tumors were found in Zymbal glands in 14 males and 6 females in 8-22 
months, in preputial glands in 2 males in 20-22 months and in 1 female in 13
months, in the skin in 2 males in 18-23 months and 1 female in 16 months, in
the mammary gland in 5 females in 13-22 months, in the forestomach in 3 males 
in 21-25 months, in the liver of 1 male in 23 months, and in the uterus of 1 
rat in 22 months. Four other tumor sites were reported for male rats: one
tumor of the small intestine in an unreported induction time, two tumors of 
the hematopoietic system in 12 and 23 months, one thyroid tumor in 25 months, 
and one lung tumor in 22 months. Various multiple tumors were found. No
sarcomas were found at the site of injection. Only one of 50 control rats
injected sc with sunflowerseed oil developed a tumor, a sarcoma associated 
with a parasitic cyst [34].
In the second experiment, pellets of o-tolidine were used [33]. In this 
experiment, 20 males and 20 females received weekly sc implants of one pellet 
containing 20 mg of o-tolidine and 10 mg glycerin for 14 months.
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Approximately the same site was used each time for implantation, and the total 
dose for each rat was 1.22 g. Autopsy procedures were the same as those used 
in the first experiment. It took 12 months for the first tumor to appear in 
rats of either sex, at which time 16 males and 20 females were still living. 
The tumor that appeared earliest and affected the greatest number was, again, 
in Zymbal glands; six males and five females developed tumors of the Zymbal 
glands in 12-18 months. Seven females had mammary tumors in 12-23 months. 
One male and one female showed skin tumors in 17 and 18 months. Three males 
developed liver tumors in 15-20 months. One male had angiosarcoma in the area 
of the forelimb in 14 months, another showed neurosarcoma around the ear in 15 
months, and a third had a tumor of the hematopoietic system after 20 months. 
One female had a lymphangioma in the neck after 20 months. Only one rat, a 
male, showed a tumor, diagnosed as a rhabdomyosarcoma, at the site of 
implantation in 20 months. In all, neoplasms were found in 23 rats (64%). 
Six rats had multiple tumors involving chiefly the skin and the liver. By the 
18th month, three males and five females were alive.
The third experiment [33] was similar to the second, except that the o- 
tolidine in the implanted pellet was subjected to ultraviolet irradiation to 
"oxidize" the o-tolidine photochemically. It was not stated why the authors 
concluded that application of ultraviolet radiation would oxidize o-tolidine. 
Twenty-four males and 24 females were used. As in the first and second 
experiments, the onset and characteristics of tumors were noted and confirmed 
when necropsies were performed. Tumors were first observed during month 11. 
Thirty-two rats were then alive, 18 males and 14 females. Six males and two 
females survived for 18 months. Neoplasms appeared in 25 rats (52%), 15 males 
and 10 females, and 6 of these had combinations of tumors at different sites. 
Among the males, nine had tumors of Zymbal glands in 11-19 months, four had 
tumors of the skin in 16-19 months, one had an intestinal tumor in 15 months, 
one had a tumor of the submaxillary salivary gland in 18 months, and one had a 
subcutaneous sarcoma, diagnosed as a rhabdomyosarcoma, at the site of 
implantation. Among the females, seven had Zymbal gland tumors in 12-16 
months, one had a tumor of the mammary gland in 19 months, three had skin 
tumors in 14-19 months, and one had a tumor of the hematopoietic system in 17 
months.
Retention of o-tolidine in the subcutaneous tissues at the sites of 
injection and implantation was studied in the fourth experiment [33]. Fifteen 
rats of unreported sex were injected sc once with 20 mg of o-tolidine in 
sunflowerseed oil; after 1-7 days, the subcutaneous tissue was excised for 
determination of o-tolidine content. Similarly, a pellet containing 20 mg of 
o-tolidine was implanted in each of 10 rats (number of each sex not reported), 
and tissue from the implant site was taken for o-tolidine determination after 
7 days. In 2 samples, 0.24-1.65 mg of o-tolidine were found at the site of 
administration of the oil suspension 24 hours after sc injection; trace 
amounts were found after 48 hours in 2 samples and 168 hours in 10 samples. 
The locus of injection was not described. Seven days after implanting a 
pellet containing 20 mg of o-tolidine, 5-13.5 mg were found at the site of 
implantation in 10 samples.
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In the fifth experiment, the amounts of free and bound aromatic amines 
were determined by diazotization from samples of the liver, kidneys, spleen, 
omentum, and Zymbal glands of 12 rats that had received daily sc 20-mg 
injections of o-tolidine in oil for 8 months [33] . The analytical method was 
reportedly capable of distinguishing aromatic amines from naturally occurring 
primary and secondary amines [36]. Eleven rats were used as controls. The 
highest amine content, expressed as jug/g of organ weight, was found in Zymbal 
glands, 246 bound and 26 free. The kidneys contained less total amines, 117 
bound and 38 free, followed by the omentum with 120 bound and 19 free, the 
spleen with 90 bound and 35 free, and the liver with 90 bound and 32 free. In 
the control animals, Zymbal glands contained 31 bound and 11 free, the kidney 
had 18 bound and 17 free, the omentum had 31 bound and 11 free, the spleen 
contained 15 bound and 19 free, and the liver had 31 bound and 11 free. The 
standard error associated with all these weight averages was around 5 ¿Jg/g. 
The low amine content of the omentum suggested to the authors that o-tolidine 
distribution does not depend primarily on its lipid solubility.
Results of microscopic studies of all tumors found in rats from the first 
three experiments were discussed together [33] . Most of the tumors of Zymbal 
glands were diagnosed as squamous-cell carcinomas, some were adenocarcinomas 
or sarcomas. Lung cancer in one rat was attributed to metastasis from a
squamous-cell carcinoma of Zymbal glands. Tumors found in the preputial 
sebaceous gland were diagnosed as one squamous-cell carcinoma, one adenoma, 
and one sebaceous carcinoma. Most of the skin tumors were epitheliomas 
arising from hair follicles, rarely from sebaceous or sweat glands. Tumors of 
mixed types occurred frequently, and both basal-cell carcinoma and 
spinocellular carcinoma were reported. Both benign and malignant mammary
tumors were found. Most malignant mammary tumors were papillary 
cystadenocarcinomas. A few carcinomas were cribriform in appearance. Two 
rats had squamous metaplasia of the glandular epithelium. Five rats from the 
second experiment had benign fibromas arising from fibroadenomas. One rat in 
the third experiment had a fibroadenoma of the mammary gland. Tumors of the 
liver occurred in single or multiple nodules. Both benign hepatomas and 
hepatocellular carcinomas were found. A few rats had cystadenomas of the bile 
ducts. In one rat, liver carcinoma metastasized to the lung. The tumors of 
the forestomach were multiple, squamous-cell, cornified papillomas with a 
cauliflower appearance. Intestinal tumors appeared in two rats; one developed 
adenocarcinoma of the small intestine and the other had carcinosarcoma of the 
large intestine with multiple peritoneal metastases . One mixed tumor of the 
submaxillary salivary gland occurred. Four rats had tumors of the 
hematopoietic system, one had reticulosarcoma of the liver with multiple 
peritoneal visceral metastases, two had reticulosis with multiple visceral
foci, and one had myeloid leukemia with enlargement of the liver and spleen.
The tumors found at the site of administration were polymorphous subcutaneous 
neoplasms with giant cells; they were suggested to be rhabdomyosarcomas. 
Various solitary tumors were found, including pulmonary cystadenocarcinoma, 
uterine leiomyosarcoma, thyroid adenoma, angiosarcoma in the region of the 
forelimbs, lymphangioma of the neck, and neurosarcoma of the ear [33]. In 
another experiment, the one rat tested had a tumor of the heart that the 
authors suggested was a rhabdomyosarcoma [37].
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Pliss and Zabezhinsky [33] concluded that o-tolidine is a carcinogen and 
suggested that its carcinogenic effects may be caused by unidentified 
metabolites rather than by the compound itself. The high frequency of tumors 
in structures of ectodermal origin, they suggested, was related to the 
accumulation of o-tolidine or its metabolites in excretory organs, such as 
sebaceous glands. Pliss [34] also concluded that a single methyl group ortho 
to the amino group reduced the likelihood of liver tumors, but that
substituting additional methyl groups in the aminobiphenyl molecule increased 
the possibility of rats developing liver tumors. The evidence in this paper
[34] to support these conclusions is weak. Pliss [35] inferred that the
carcinogenic properties of o-tolidine were manifested after its conversion to 
carcinogenic metabolites because all tumors except one formed in a number of 
distant tissues and did not form at the sc injection sites. He also observed 
that more males than females developed tumors, particularly of specialized 
sebaceous glands, eg, Zymbal glands.
Saffiotti et al [30] and Sellakumar et al [38] conducted similar
experiments on hamsters, administering o-tolidine in oral doses of 0.1-1%. 
Their results were negative.
The papers by Spitz et al [15] and Pliss and Zabezhinsky [33] present 
considerable evidence of the carcinogenicity of o-tolidine in rats. No
bladder tumors were found, but they were not expected because even benzidine
does not cause bladder tumors in rats [31].
In 1973, Freeman and coworkers [39] tested the use of cell culture
transformation to indicate the carcinogenic potential of several chemicals, 
one of which was o-tolidine. The chemicals were tested in cell cultures from 
the Fill pool of rat embryo cells inoculated with Rauscher leukemia virus 
(RLV). The cultures showed no spontaneous transformation for at least 50 
passes by RLV, or by chemical carcinogens alone, but did show transformation 
with both the virus and the chemical. One set of cultures showing
transformation was held indefinitely; another was subdivided at 2-week 
intervals, with half being held indefinitely and half being subdivided again. 
When transformation occurred frequently, it could be detected in the original 
cultures and was more pronounced in daughter cultures. When transformation 
was rare, the cultures had to be subdivided at least once before it was
detected. Transformation was recognized by macroscopic foci of spindle cells 
without polar orientation or contact inhibition; these cells were tumorigenic 
when transplanted into newborn Fischer rats.
o-Tolidine was found to be toxic to the cell cultures at 199 n%fval [39] . 
At 50 jug/ml» there were well-defined foci of spindle cells. At 10 and 5 
pg/ml, transformation was still apparent, but the foci were less well defined. 
No effects were seen at 1 Mg/ml• Although this test uses an in vitro system 
and is not well established, its usefulness in this case is supported by the 
findings of tumorigenesIs when the transformed cells were transplanted into 
rats. Similar findings with known carcinogenic chemicals, eg, 4-aminobiphenyl 
and dichlorobenzidine, lend additional support.
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Seiler [40] applied the Friedman-Staub screening test to a variety of 
chemical mutagens and carcinogens. This procedure uses the amount of 
tritiated thymidine incorporated into DNA as an indication of DNA damage, and, 
in turn, of carcinogenicity or mutagenicity. The smaller the amount of 
radiolabeled thymidine incorporated into DNA, the greater the indication of 
damage. Adult male mice (23-28 g) were given oral 100 mg/kg doses of o- 
tolidine. Controls were given only thymidine. o-Tolidine administration 
resulted in incorporation of 77.6% of the amount of thymidine incorporated by 
controls, a decrease reported to be statistically significant. Overall, 86% 
of the known carcinogenic and mutagenic chemicals tested depressed DNA 
synthesis, while only 10% of noncarcinogenic and nonmutagenic compounds did 
so. Among the chemicals that demonstrated carcinogenicity in vivo, all the 
polycyclic hydrocarbons tested, all three azo dyes tested, and six of the 
seven aromatic amines tested were also transforming agents on this assay. 
This study [40] supports the finding of Freeman and coworkers [39] that o- 
tolidine damages DNA in mammalian cells.
In 1976, Shimizu and Takemura [41] reported that o-tolidine at an 
unreported concentration exerted a positive mutagenic effect on two strains of 
bacteria used in the Ames test, Salmonella typhimurium TA 98 and TA 100. The 
Ames test indicates mutation by testing a chemical's ability to change a 
microorganism's requirement for a specific nutrient, usually histidine. The 
magnitude of this effect was not reported. The authors compared their results 
favorably with the positive evidence for carcinogenicity of o-tolidine 
reported by Pliss in 1970, but did not cite the specific reference.
o-Tolidine base was evaluated for mutagenic activity in another study 
[42]. Microbial plate assays were performed with Saccharomyces cerevisiae D4 
and Salmonella typhimurium TA 1535, TA 1537, and TA 1538, both with and 
without metabolic activation from tissue homogenate prepared from the lungs, 
liver, and testes of ICR random-bred mice, Sprague-Dawley rats, and rhesus 
monkeys. Tests were done in duplicate with positive and negative controls. A 
test was considered positive if spontaneous reverse mutations in Salmonella 
and mitotic recombination in Saccharomyces increased tenfold or more above 
background levels. The initial results were inconclusive, but the 
nonactivation assays and tiie activation assays with mouse liver indicated that 
the number of revertants with Salmonella typhimurium TA 1538 was slightly 
increased. Additional tests were performed using the same protocol, except 
that a fivefold or greater increase was considered positive. This time, no 
mutagenic activity was detected. The experimenters concluded that o-tolidine 
base was not mutagenic.
In 1977, Ferretti et al [43] tested the mutagenic effects of o-tolidine 
and several other compounds on Salmonella typhimurium TA 1538. The standard 
Ames procedure was followed. The results, expressed as a ratio of the average 
number of revertants/plate with activation by liver microsomal enzymes to the 
revertants/plate without activation, were 371:18 for benzidine, 422:12 for o- 
dianisidine, and 80:6 for o-tolidine. The authors judged this to be evidence 
that benzidine, dianisidine, and o-tolidine were mutagenic. None of the 
compounds showed mutagenic activity in the absence of microsomal activation;
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this is consistent with suggestions that the carcinogenic effect of o-tolidine 
in rats is due to a metabolite of o-tolidine, rather than to o-tolidine itself 
[33].
Golub [44] administered o-tolidine to pregnant BALB/c mice at a daily sc 
dose of 2 mg in 0.1 ml of sunflowerseed oil. The mice were killed after 19-20 
days, and the embryonic kidneys were obtained for organ culture. A total of 
55 organ cultures were obtained from controls and 25 from mice given o- 
tolidine. Organ cultures were examined for 20 days. Epithelial hyperplasia 
and other undescribed cellular changes were noted in the experimental cultures 
but not in controls, suggesting that o-tolidine had transplacental effects on 
the embryos of pregnant mice.
Wilson [45], in 1955, reported on the teratogenic effect of o-tolidine and 
dyes with o-tolidine nuclei, eg, trypan blue. A total of 30 mg of o-tolidine 
was administered by sc injections on 3 successive days to each of 10 young 
adult albino rats after pregnancy had proceeded for 1 week. No control group 
was reported. Pregnancy continued until the 20th day, when the mothers were 
killed and the offspring examined. A total of 109 implantations occurred in 
the 10 rats given o-tolidine; of these, no embryos were malformed, but 8% were 
resorbed. Basing their conclusion on these data, the authors stated that "o- 
tolidine alone, without azo linkages and naphthalene side rings, was totally 
ineffective" as a teratogen.
Korotkova and Tokin [46], in 1968, immersed colonial or single sponges in 
100 ml of sea water containing 300 mg of o-tolidine for 45 minutes. Control 
sponges were treated similarly, but India ink was substituted for o-tolidine. 
All sponges were then observed for 11 days in running sea water. Water 
temperature was held at 7-9 C at all times. Both living and fixed specimens 
were studied. Sponges immersed in o-tolidine showed epithelial damage and 
mitotic activity accelerated to 2-3 times the rate of regenerating tissue. 
Colonial sponges were more susceptible to o-tolidine than were single sponges, 
as shown by earlier budding and abnormal growth. Mitotic activity and budding 
of control sponges were unaltered.
(c) Metabolism
The metabolism of o-tolidine has been investigated in dogs [47,48], 
rabbits [48], rats [49], and in occupationally exposed workers [48,50]. 
Although the experimental data are sparse, the available evidence allows a 
comparison between humans and other mammalian species with respect to the 
metabolic fate of o-tolidine in vivo.
Urine of workers occupationally exposed to undefined quantities of o~ 
tolidine was reported to contain o-tolidine, N,N’-diacetyl-o-tolidine, and 5- 
hydroxy-o-tolidine and its conjugates [22,50]. Although N-acetyl-o-tolidine, 
a known metabolite in animals [48], was not identified in the urine of 
workers, it probably occurs as an intermediate during the biosynthesis of 
N,N'-diacetyl-o-tolidine. Benzidine metabolites found in the urine of 
occupationally exposed workers are reported to include benzidine (3.5-5.6%),
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N-acetylbenzidine (5.1-10%), N,N'-diacetyl benzidine (5.1-10.0%), and 3- 
hydroxybenzidine and conjugates (78.5-89.7%) [51]. These data suggest that 
the metabolic pathways for o-tolidine (3,3'-dimethylbenzidine) and benzidine 
are qualitatively similar in the human organism. The first steps in the 
pathways appear to be acétylation of the amino groups and introduction of the 
phenolic group on the aromatic ring.
Engelbertz and Babel [48] measured the concentration of aromatic amines 
after acid hydrolysis in the urine of workers occupationally exposed to o- 
tolidine. The hydrolysis was carried out to convert any N-acetyl-o-tolidine 
or N,N'-diacetyl-o-tolidine present into free aromatic amines. The urine 
samples from eight workers in o-tolidine production units contained 0.050- 
0.250 mg of aromatic amines, reported as o-tolidine equivalents, per 100 ml. 
The authors also measured the concentrations of aromatic amines in 12 urine 
samples collected intermittently from one worker during a 24-hour period. The 
highest concentrations of aromatic amines were measured within 6 hours after 
beginning work. The concentration in the last sample was about one-fifth of 
the maximum value, which indicates that o-tolidine had a half-life of a few 
hours in this individual. Despite the limited nature of this study, it 
confirms that o-tolidine was absorbed by occupationally exposed workers and 
was rapidly metabolized and excreted.
The metabolites of o-tolidine reported to occur in the blood or urine of 
dogs include o-tolidine, N-acetyl-o-tolidine, N-N'-diacetyl-o-tolidine, 5- 
hydroxy-o-tolidine or its conjugates, and o-tolidine-5-sulfate or o-tolidine- 
5-glucuronide [47,48,52]. A pharmacokinetic study of o-tolidine in dogs 
following exposure by different routes of administration was reported by 
Engelbertz and Babel in 1956 [52] . The analytical technique they employed was 
based on colorimetric determination of the diazotization products of the free 
aromatic amines. Consequently, the method might not distinguish between o- 
tolidine and any of its aromatic metabolites containing free amino groups.
The maximum color intensity of free aromatic amines in the blood was 
reached about 2 hours after a 100-mg iv dose was administered [52] . Color 
intensity then decreased continuously with time. The half-lives of o-tolidine 
and its metabolites in canine blood appeared to be less than 8 hours. After 
the dogs received 200 mg in their food, the maximum concentrations of o- 
tolidine and related amines in the blood also occurred in about 2 hours, and a 
similar half-life was observed. These data indicate that o-tolidine is 
rapidly absorbed through the gut following oral ingestion. The measured rates 
of clearance of aromatic amines and acetylated derivatives from the blood are 
consistent with a rapid metabolism and excretion of o-tolidine and its 
metabolites. The analytical techniques employed did not allow for assessment 
of the fraction of the total dose of o-tolidine or its metabolites in the 
blood, so that conclusions on the pharmacokinetics of o-tolidine and all of 
its metabolites are not possible. In parallel experiments, the investigators 
observed similar rates of absorption, metabolism, and excretion of benzidine 
and its metabolites.
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Engelbertz and Babel [48] also conducted feeding studies to investigate 
the metabolic fate of N-acetyl-o-tolidine and N,N'-diacetyl-o-tolidine in dogs 
and rabbits. They devised an extraction procedure to separate the urinary 
metabolites. They observed that orally administered N-acetyl-o-tolidine was a 
precursor of both o-tolidine and N,N’-diacetyl-o-tolidine in the urine. 
Similarly, they reported that N,N'-diacetyl-o-tolidine was a precursor of both 
N-acetyl-o-tolidine and o-tolidine. The report suggests that a facile 
metabolic interconversion of o-tolidine and its acetylated derivatives may 
occur in dogs and rabbits.
An investigation of the metabolism of benzidine in vitro has recently been 
reported by Morton et al [53,54]. Using extracts prepared from rat, mouse, 
guinea pig, and hamster livers, the investigators demonstrated the formation 
of diacetylbenzidine from acetyl CoA and benzidine. Subsequent oxidation of 
diacetylbenzidine to N-hydroxydiacetylbenzidine and 3-hydroxydiacetylbenzidine 
was found to be catalyzed by microsomal enzymes. The shift of the acetyl 
moiety from the nitrogen to the oxygen atom, catalyzed by N-0- 
acetyltransferase, yielded a highly reactive species which was shown to bind 
to nucleic acids covalently. This reaction sequence for benzidine parallels 
the reaction sequence for other carcinogenic aromatic amines, such as 2- 
aminofluorene [55]. Consequently, these in vitro studies suggest that a 
fraction of the absorbed o-tolidine will also be metabolized to a similar 
reactive intermediate.
After the administration of a single ip dose of o-tolidine to a dog, 
Sciarini and Meigs [47] recovered only about 40% of the dose in the urine as 
o-tolidine or its known metabolites. The fraction of the dose that remained 
and was excreted in the feces and the fraction that was covalently bound were 
not determined. The binding of aromatic amines to tissues during long-term 
exposure of rats to o-tolidine was investigated by Pliss and Zabezhinsky [33]. 
After weekly sc injections of 20 mg were given to each animal for 8 months, 
the authors measured the distribution of aromatic amines using a diazotization 
method. The content of free and bound aromatic amines in different organs was 
determined 3 days after the last administration of o-tolidine. Bound aromatic 
amines were measured after hydrolysis of tissue homogenates in 2N hydrochloric 
acid. Relative to the control tissues, an increased amount of both free and 
bound aromatic amines was observed in all examined tissues— the liver, 
kidneys, spleen, omentum, and Zymbal glands. The largest Increase of bound 
aromatic amines (more than eightfold) occurred in the kidneys and Zymbal 
glands. Since the increase in aromatic amines was observed 3 days after 
administration of the last dose and since the in vivo half-life of o-tolidine 
and its metabolites is only a few hours, these observations are consistent 
with the formation of a reactive intermediate that covalently binds to 
cellular macromolecules.
The available evidence [22,47,48,50-52,55,56] indicates that the fates of 
o-tolidine and benzidine in biologic systems are closely related, probably 
because of similar metabolic mechanisms. Although quantitative differences in 
metabolism do occur, these differences are insufficient to allow for 
postulation of major differences in the mechanisms of action of o-tolidine and 
benzidine.
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Correlation of Exposure and Effect
There is some evidence of carcinogenicity in rats [33,57], possible 
carcinogenicity in dogs [29], altered enzyme activity in rats [49], and 
possible evidence of mutagenicity and teratogenicity in mammalian cell 
cultures. Little information is available on the toxic effects of o-tolidine 
on humans. The information that is available for humans and animals can only 
be used as a qualitative index of effects.
Investigators exposed to o-tolidine at unknown concentrations have 
experienced nasal irritation [16]. Humans absorb o-tolidine through intact 
skin and excrete o-tolidine and its acetylated and hydroxylated metabolites in 
urine [17,22,50]. Urinary metabolites of o-tolidine were detected in the 
urine of a volunteer after an 8-hour application of 200 mg under a glove, but 
when 100 mg of o-tolidine were applied to the skin for 48 hours there was no 
detectable urinary excretion of quinonizable substances [17]. Skin irritation 
has not been reported in humans.
The results of animal experiments have provided some limited data on the 
uptake of o-tolidine. The half-life of o-tolidine in blood after 100 
milligrams of the compound was administered iv, seems to be less than 8 hours 
[52]. When o-tolidine was ingested with food, maximum blood concentrations of 
o-tolidine were reached in 2 hours, indicating that o-tolidine is rapidly 
absorbed through the gut. Similar findings were observed in dogs in parallel 
experiments conducted with benzidine [52]. After weekly sc injections of o- 
tolidine in rats [33] , the highest observed increase in bound aromatic amines 
occurred in the kidneys and Zymbal glands. These findings are of interest 
because of the reports of kidney damage in rats and rabbits [16,26] and 
carcinoma of the Zymbal glands in rats [16,33] as summarized in the discussion 
which follows.
The possibility of kidney damage should be considered, but not much 
information is available on this aspect of o-tolidine toxicity. There is one 
report of renal failure in rabbits fed o-tolidine at 1 g/day for 3 days [16] 
and one report of kidney damage, especially in the uriniferous tubules, in 
rats fed o-tolidine at a 5% concentration mixed in olive oil mixed with rice 
at 20 cc olive oil solution/kg of rice [26].
Carcinogenicity, Mutagenicity, Teratogenicity, and Effects on Reproduction
Cancer of the urinary bladder [15] has been found in workers making dyes 
from a variety of hazardous substances, o-tolidine among them, but, because 
exposures have been to two or more biphenyl amines, there is no strong 
evidence either to indicate that o-tolidine alone causes cancer in humans or 
to absolve it as a human carcinogen. Cancer has not been reported in humans 
exposed to o-tolidine alone, although cancer of the urinary tract has 
developed in workers exposed to both benzidine and o-tolidine [20,21]. The 
single report of bladder cancer in one of four dogs fed 200 mg of o-
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tolidine/day for 8-9 months [29] does not establish, but is consistent with,
the hypothesis that o-tolidine, like benzidine, may induce urinary tract 
cancer in animals.
Cancer has been found in the Zymbal glands, skin, forestomach, lungs, bone 
tissues, and hematopoietic system in rats exposed to o-tolidine [32,33], but 
it has not been demonstrated in hamsters according to a brief commentary by
Saffiotti et al [30]. Most of the experiments with rats have used repeated
high doses (0.001-1.29 mg) to induce tumors. Single doses (100 mg/kg) have 
altered enzyme activities in rats [49], but tumors have not been reported.
It has been suggested that a single methyl group ortho to the amino group 
in the diphenyl diamine molecule reduces the likelihood of liver tumors in 
rats, but the substitution of additional methyl groups would increase the 
possibility of developing liver tumors [62]. However, the administration of 
3,5,31,5'-tetramethylbenzidine to rats [32] did not produce tumors of the 
liver.
o-Tolidine resembles benzidine in structure, in physical and chemical 
properties [1,2,58], and in metabolism [47,48,50-52,55,56,58-60], The sites 
and microscopic appearance of tumors observed in rats following o-tolidine 
administration [33] and dihydroxybenzidine administration [61] are similar. 
Benzidine, an aromatic amine which is accepted to be a human carcinogen (29 
CFR 1910.1010), has not produced bladder cancer in rats [31]. Both o-tolidine 
and benzidine administration to rats do, however, result in cancer of the 
Zymbal glands [32,62]. The similarity between o-tolidine and benzidine in 
chemical structure, in absorption of both compounds by all routes (including 
the skin), in metabolism to acetylated and hydroxy compounds, in excretion 
preferentially by the urinary route, and in the induction of tumors of the 
Zymbal glands in rats suggests that o-tolidine can cause bladder tumors in 
dogs and humans as does benzidine. In addition, o-tolidine probably is a
factor, along with benzidine, in cases of human bladder cancer following mixed 
exposures to these chemicals, such as those reported by Macalpine [21].
Pliss [62] suggested that the accumulation of o-tolidine or its 
metabolites in excretory organs, such as sebaceous glands, is related to the 
high frequency of tumors in structures of ectodermal origin. The results of 
research by Holland et al [32] lend support to the suggestion.
Although one study [42] did not agree, the indications of mutagenicity of 
o-tolidine in bacteria [41,43], the influence on DNA synthesis in mouse testes 
[40], the influence on organ cultures derived from pregnant mice treated with 
o-tolidine, and in vitro transformation of rat embryo cells [39] support the 
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The concentration of biphenyl amines in the air at the plant manufacturing 
o-tolidine around 1950 ranged from 2 to 87 ng/cu m and averaged about 20 
¿tg/cu m [22], but specific o-tolidine levels were not given. Additional 
-Informat--inn on o-tolidine levels in the workplace environment was not found. 
However, environmental concentrations of o-tolidine for manufacturers and 
users can be only roughly estimated from current processing information. 
Because batch processing is used by both manufacturers and users, with the 
result that environmental levels of o-tolidine fluctuate from zero during off- 
production periods to a maximum when o-tolidine is produced or used, worker 
exposure to o-tolidine is expected to be intermittent, with the frequency of 
exposure depending on the frequency of production.
For manufacturing facilities, except for accidental spills or leaks, 
environmental levels would probably be highest near operating filter presses 
and driers. Bulk quantities of o-tolidine are also handled in dye
manufacturing; 1,500-2,000 pounds are used for each batch operation. For 
these facilities, high levels can be expected when o-tolidine is weighed and
when the reactor is being charged with o-tolidine. Other users of o-tolidine
handle less than 200 pounds of o-tolidine per year in small quantities, 
generally milligrams [63]. It is expected that their exposure to airborne o- 
tolidine would be intermittent and possibly negligible.
o-Tolidine can enter the body by any route, particularly inhalation and 
skin contact [17,22]. A significant hazard comes from contaminated clothing 
[10,22,64]. Personal hygiene, removal of contaminated work clothing,
separation of work clothing from street clothing, and showering at the end of
the workshift have greatly reduced the absorption of o-tolidine [10,22].
Control of Exposure
Inhalation and skin absorption of o-tolidine can be minimized by proper 
ventilation, cleaning operations not requiring direct exposure of workers, 
prompt cleanup and decontamination procedures using liberal amounts of water, 
employee education and attention to personal hygiene, and full-body protective 
equipment when necessary. In one case, a worker’s urinary excretion of 
aminobiphenyl compounds was reduced 80% by attention to personal hygiene [22].
Proper ventilation is an important means of controlling respiratory
exposure to o-tolidine and will help to minimize skin exposure by reducing the
amount of o-tolidine available to settle out of the air. Guidelines for
ventilation systems may be found in Industrial Ventilation— A Manual of
Recommended Practice of the American Conference of Governmental Industrial
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Hygienists (ACGIH) [65] and in Fundamentals Governing the Design and Operation 
of Local Exhaust Systems of the American National Standards Institute (ANSI) 
[ 6 6 ] .
The most effective engineering control measure is enclosure of unit 
operations and processes. Closed systems are most effective if they are 
operated under negative pressure with respect to surrounding uncontaminated 
areas, and they are only effective if their integrity is maintained. This can 
be ensured by a program of periodic maintenance, especially of equipment 
parts, eg, gaskets and seals that are subject to wear, by frequent inspections 
for and immediate repair of leaks, and by the use of pressure-failure alarms 
in enclosures, hoods, and ductwork.
An alternative or supplement to closed processes is local exhaust 
ventilation used at all sources of o-tolidine emission. The' hood should be as 
close to the emission source as possible and shaped to control the area of 
contamination. Airflow into the exhaust hood should be directed away from the 
worker, and the capture velocity of the exhaust hoods should be high enough to 
overcome opposing air currents and the kinetic velocity of generated dust 
particles within the working environment, including those caused by movements 
of the workers. A minimum airflow of 150 fpm is recommended, but final 
determination should be made by an industrial hygienist. An industrial 
hygiene survey should be performed to determine the proper hood design and 
capture velocity for the facility.
With the exception of o-tolidine manufacturers and dye makers, each user 
facility generally consumes less than 200 pounds/year. For these facilities, 
local exhaust ventilation in the form of a laboratory-type hood or glove box 
may be effectively used for batch operations in which o-tolidine is weighed, 
converted into a concentrated acid solution, or diluted; in repackaging 
operations; and in laboratory activities involving research or quality 
control. A properly designed and maintained laboratory hood or glove box can 
confine the area of contamination to the hood or glove box itself, thereby 
simplifying control procedures for preventing skin contact with and inhalation 
of o-tolidine. The hood or glove box should be located away from heavy 
traffic aisles, doorways, and supply grills. A minimum exhaust volume for the 
laboratory hoods of 150 cu ft/minute/sq ft (45 cu m/minute/sq m) of door area 
is recommended [65], but final determination should be made by an industrial 
hygienist. Hoods should be inspected monthly for the first 6 months and 
quarterly thereafter [65].
o-Tolidine is used in some batch operations as an intermediate in dye, 
pigment, and urethane production. Bulk quantities up to 1,500-2,000 pounds 
are weighed and then dumped into reactors to be chemically converted into the 
final product. In such operations, o-tolidine is generally handled for less 
than 1 hour. Dust emissions from the weighing operation should be controlled 
by the use of local exhaust ventilation. The hood should enclose as much of 
the scale as possible without interfering with the worker's performance.
Local exhaust ventilation can also be used to control dust in the charging 
or reaction vessels. However, an alternative approach is to operate the
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reactor under negative pressure relative to the working environment. Negative 
pressure within the system should usually control a billowing effect that has 
been reported during the charging of reaction vessels in dye production [10].
Handling o-tolidine in the wet-cake or paste form provides additional 
safeguards by reducing the amount of dust liberated [10]. The liberation of 
dust may also be reduced by converting the o-tolidine base to its larger 
crystalline salt structure [10]. If possible, premeasured units of dry o- 
tolidine base or salts should be opened under water or other suitable liquid 
to reduce the amount of dust released when the package is opened.
Environmental Sampling and Analytical Methods
(a) Sampling
Because airborne o-tolidine is typically an aerosol, filters or impingers 
are most appropriate for personal air sampling, although no studies have been 
found on this point. Filters are effective for particulates. Glass-fiber 
filters are recommended to minimize pressure drop. They are clean, self- 
contained, and convenient. It is recommended that the filter be backed in 
series by silica gel to minimize losses from vaporization of the sample. This 
system of a filter backed by silica gel has been used successfully in sampling 
for benzidine [67] and other related biphenyl amines. Alternatively, 
impingers may be substituted for filters or filter and silica gel tandem 
devices for sampling. Hydrochloric acid [68] and distilled water [69] have 
been used as collecting media, but because recovery rates were not provided, 
their effectiveness in capturing o-tolidine cannot be evaluated. Because of 
the difficulties involved in obtaining breathing zone samples with impingers, 
filters are recommended to sample air in the breathing zone of workers. 
However, stationary impingers may be used for supplementary area sampling. 
Sampling with impingers should be avoided unless precautions are taken to 
prevent sample losses through foaming and solvent loss.
(b) Analysis
Concentrations of airborne o-tolidine should be kept as low as possible to 
minimize worker exposure through both inhalation and skin absorption. The 
following discussion reviews several methods of analyzing o-tolidine and 
related compounds in air for environmental monitoring and in urine for 
biologic monitoring.
Matrka et al [70] described an oxidimetric (potentiometric) titration 
method for o-tolidine determination using cerium (IV) sulfate. Standards were 
prepared with 42-106 mg of o-tolidine dissolved in 45 ml of 0.1 N hydrochloric 
acid at 20 C. The indicator electrode was glossy platinum, the comparison 
electrode saturated calomel. The o-tolidine solution was titrated with 0.05 N 
cerium disulfate solution. The error between amounts of o-tolidine weighed 
and calculated after titration varied between 0.2% and 0.4%. Titration 
usually overestimated the actual amount. The authors mentioned other 
techniques of titration for o-tolidine, including titration with p-toluene 
sulfonic acid, but did not quantitatively compare those techniques with their
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own. This oxidimetric method has a clearly marked end point but lacks 
specificity. The sensitivity of the method was not given, but this method 
probably is not sensitive at the microgram level.
Fluorometric [6,71,72] and colorimetic [68,69,73-76] methods have been 
developed for the analysis of biphenyl amines, including o-tolidine. The 
fluorometric techniques depend on the property of aromatic amines to fluoresce
[6] or form fluorescent derivatives with a suitable reagent [71,77].
One method that uses the fluorescence of the amines has been described by 
Bowman et al [6]. The method has been successfully used to analyze biologic 
samples, such as blood and urine, for o-tolidine and required extraction of 
the compound with suitable solvents. For urine, 10 N NaOH was added to the 
sample, which was then extracted with benzene. A recovery of 90% was 
reported. The limits of detection for o-tolidine and its salts were 2 ng/ml 
(2 /ig/liter) . The major disadvantage of the method is its inability to 
separate o-tolidine from such related compounds as benzidine in a mixture.
Techniques in which a fluorescent derivative is formed generally use 
either o-phthalaldehyde or fluorescamine [71]. However, o-phthalaldehyde 
could not be applied to o-tolidine analyses because it failed to form a 
fluorescent derivative when reacted with o-tolidine [71]. Fluorescamine forms 
an unstable fluorescent derivative with aromatic amines [71], so it is 
probably unsuitable for o-tolidine fluorometry, but could be suitable for 
conventional colorimetry as discussed later.
In colorimetry, the biphenyl amine is reacted with a suitable reagent to 
form a colored complex, which is measured spectrophotometrically. A variety 
of colorimetric techniques have been developed, primarily for benzidine 
analysis of biologic specimens, and differ mainly in the reagent used. These 
methods have been used successfully with other related biphenyl amines and in 
the analysis of air samples, but only a few have actually been adapted to o- 
tolidine analysis. These include a qualitative method [75], a chloramine-T 
test [69,76], a sodium hypochlorite test [68,74], an N-(l-naphthyl)- 
ethylenediamine dihydrochloride test [73], and the fluorescamine reagent test 
[71]; they all use naphthoquinone potassium sulfonic acid as a reagent [48].
In the qualitative method [75] , a bromocyanogen solution is mixed with the 
sample, giving rise to an orange to red color in the presence of o-tolidine. 
The limit of detection of this method is 50 ¿ig of o-tolidine/liter of urine. 
The method is quick and simple but lacks specificity and sensitivity for 
monitoring o-tolidine in the air and in urine. Another disadvantage of the 
method is that bromocyanogen is highly toxic.
The diazotization and coupling of o-tolidine and N-(l-napthyl)- 
ethylenediamine dihydrochloride has been used in the analysis of o-tolidine 
[73]. A violet-rose complex is obtained, and the method has a reported limit 
of sensitivity of 2-3 //g/8 cc. The maximum concentration that can be detected 
without dilution is 50 jug/8 cc (6.25 //g/cc). The diazotization method may be 
difficult to use at very low concentrations, because the diazo compound may 
rapidly decompose [78].
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Fluorescamine forms a stable yellow derivative with o-tolidine. It has 
been successfully used in the colorimetric analysis of o-tolidine and has a 
reported lower limit of 2 nmoles (0.3 Mg) [71]. Advantages of this method 
over other colorimetric methods are that the reagent is colorless, thereby 
eliminating the need for removing the unreacted reagents, and that the colored 
complex is stable.
1,2-Naphthoquinone-4-potassium sulfonic acid forms a bluish-pink complex 
in the presence of o-tolidine and has a limit of detection of 0.05 mg/100 cc
[47]. This method is not sensitive enough to monitor o-tolidine in urine 
samples.
Of the colorimetric methods that have been used for o-tolidine analysis, 
the qualitative method [75] and the 1,2-naphthoquinone-4-potassium sulfonic 
acid method [47] do not have the sensitivity required to adequately monitor o- 
tolidine in urine in the microgram range. Of the remaining four methods, the 
chloramine-T test [69], the sodium hypochlorite method [68], and the N-(l- 
naphthyl)-ethylenediamine dihydrochloride reagent method [73] are sensitive to 
o-tolidine in the microgram range but share the common problem of having an 
unstable color complex, thereby requiring quick and rapid reading.
The methods described above are nonspecific. Because o-tolidine is 
generally found in the same environment as benzidine and other biphenyl 
amines, the proper monitoring of o-tolidine in air requires a method that is 
both sensitive and specific for o-tolidine. Some investigators have coupled 
the fluorometric and colorimetric techniques discussed above with either paper 
[22,68,73] or thin-layer [6,71] chromatography. These chromatographic methods 
differ mainly in the solvents used to separate the biphenyl amines. Meigs et 
al [22] used reagent grade petroleum ether to separate o-tolidine from other 
biphenyl amines in paper chromatography but did not quantitate the o-tolidine 
present. Paper chromatography using an isobutanol, glacial acetic acid, and 
water system was coupled with the N-(l-naphthyl)-ethylenediamine 
dihydrochloride colorimetric method to obtain quantitative separation of o- 
tolidine with a level of detection of 5 ng/liter of urine [68,73]. Although 
these techniques can reach the desired level of sensitivity for monitoring o- 
tolidine in air, the procedures involved are tedious and time consuming.
Thin-layer chromatography has been used with fluorometry to obtain a 
qualitative separation of o-tolidine using a methanol solvent system [6] and 
with colorimetry using a chloroform-ethanol solvent system and 1,2- 
naphthoquinone-4-sulfonate reagent [71]. Quantitative separation of o- 
tolidine with thin-layer chromatography was accomplished using a chloroform, 
glacial acetic acid, and methanol solvent system to obtain separation followed 
by fluorescamine colorimetry [71]. The limit of sensitivity was 2 nmoles (0.3 
jug). As with paper chromatography, the primary disadvantage of this method 
[71] is the tediousness of the operation and the time required to complete 
analysis.
Bowman et al [6] used a gas chromatograph equipped with a flame-ionization 
detector to obtain separation. The column packing was 10% OV-lOl (w/w) on Gas 
Chrom Q (80-100 mesh) and operated with a helium flow of 100 ml/minute.
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Injection port and detector temperatures were 275 C and 290 C, respectively. 
A temperature-programmed chromatograph (200-280 C) was used to obtain 
separation; o-tolidine appeared at 235 C. The sensitivity of the method was 
not given, but the authors did report that the method lacked the sensitivity 
and specificity required for trace analysis of o-tolidine.
A high-pressure liquid chromatography method has been developed and 
validated for benzidine in air [67]. The method has a working range of 3-130 
jug/cu m and a limit of detection of 0.05 /ng/sample. The method is simple and 
rapid compared with paper and thin-layer chromatography. Potential 
interferences can be overcome by changing the composition of the mobile phase 
or by solvent programming. This method has not been used for the analysis of 
o-tolidine, but because of its success in the analysis of other related 
biphenyl amines (those with similar physical and chemical properties) this 
method is judged to be acceptable for the separation and quantification of o- 
tolidine at the same level of detection as benzidine.
High-pressure liquid chromatography is a simple and rapid analytical 
procedure compared with paper and thin-layer chromatography coupled with 
fluorometry or colorimetry. It has a limit of detection of 0.05 jug/sample, 
which is four times more sensitive than the most sensitive currently available 
fluorometric (0.2 ¿¿g/sample) [6] or colorimetric (0.3 jug/sample) [71] method 
adapted for o-tolidine analysis. High-pressure liquid chromatography is 
therefore recommended for the analysis of o-tolidine in air.
The fluorescamine colorimetric method [71] does not have the disadvantages 
of the other colorimetric methods discussed above. It forms a very stable 
color complex with o-tolidine and is the most sensitive of these methods. 
This additional sensitivity would be advantageous for employee protection. 
The method also uses a colorless reagent, which eliminates the need for 
extracting the unreacted reagent. For these reasons, the fluorescamine 
colorimetric method of urinary analysis of o-tolidine is recommended.
The fluorometric method of Bowman et al [6] is comparable with the 
fluorescamine colorimetric method [71] and may be used in the analysis of 
urine samples. The fluorescamine colorimetric method of analysis is preferred 
because it is easier to perform.
Biologic Monitoring
Aromatic diamines, such as o-tolidine and benzidine, are not normally 
found in the body; therefore, the detection of o-tolidine or its metabolites 
in the urine should be attributed to exposure to this compound. o-Tolidine 
may be absorbed through the lungs, the skin, or the digestive tract.
It is important to minimize or eliminate the absorption of o-tolidine by 
workers. This is done by adhering to stringent engineering controls and work 
practices. If o-tolidine or other aromatic diamines are detected by 
urinalysis, it may signal inadequacies in either engineering controls or work
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practices; however, it should be remembered that a positive indication of 
diamines in the urine may result from nonoccupational sources such as 
medication.
Meigs et al [22,64] reported a correlation between the magnitude of 
exposure to biphenyl diamines, including o-tolidine, and the amount of 
diamines detected in the urine of workers. Following an 8-hour workshift, 
workers directly exposed to biphenyl diamines excreted an average of 500 jug of 
diamine/liter of urine. Greater quantities were excreted during the summer 
months than during the winter months. Foremen excreted an average of 50 jug of 
diamine/liter of urine following a workshift. In some instances, the authors 
specifically identified which diamines were in the urine. Investigation of 
several cases revealed the presence in the urine of some diamines to which the 
worker had not knowingly been exposed, thus indicating exposure of unknown 
origin to diamines that were either previously produced or produced in other 
areas of the plant. Contaminated work clothing was discovered to be the 
source of unexpected exposure. Improved work practices and personal hygiene 
were reported to have been associated with decreased urinary excretion of 
biphenylamine compounds. Throughout the testing period, concentrations of 
biphenylamines in the workplace air ranged from 2 to 87 Mg/cu m, averaging 18 
Mg/cu m.
Further evidence of the effectiveness of improved work practices and 
personal hygiene in minimizing exposure of workers to diamines was reported by 
PF Woolrich (written communication, December 1977). Three employees worked 5 
successive days wearing the same underclothing and using the same gloves. At 
the end of the 5th day, aromatic amine concentrations of 30, 125, and 330 mg 
were determined in the work clothing of the three workers. At the end of the 
5th day, the corresponding concentrations of aromatic amines, measured as 
quinonizable substances, in the urine of the three workers were 274, 501, and 
602 jug/liter, respectively, suggesting a relationship between the absorption 
of diamines (including o-tolidine) and skin contact with contaminated 
clothing.
The time span of urinary diamine excretion may be estimated from results 
reported by Meigs and coworkers [22] . After an accidental drenching with 
dichlorobenzidine, one worker had an excretion rate of urinary diamines which 
peaked on the day of exposure (1.13 mg/liter) and which returned to a baseline 
level (.043 mg/liter) the next day. This suggested to the authors that urine 
samples should be obtained near the end of the workshift.
Although these studies are very limited, it is concluded that the presence 
of biphenylamines in the urine of employees working with o-tolidine represents 
absorption of the compound. The measurement of urinary diamines is more of a 
diagnostic practice than one of compliance. Biologic monitoring provides 
employers with a valuable measurement technique that can be used to verify o- 
tolidine exposure in the individual employee.
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V . WORK PRACTICES
Health hazards from o-tolidine can be controlled by minimizing exposure 
through inhalation and skin contact and by a health and safety program that 
combines good work practices and engineering controls.
The area where o-tolidine is manufactured, processed, used, repackaged, 
released, handled, or stored should be designated a regulated area. This is 
not intended to include areas where o-tolidine tapes or kits are used for 
testing purposes. Skin contact with o-tolidine should be avoided. Access to 
the regulated area should be limited to employees having assigned duties 
within the area. A daily entry roster should be kept of all employees 
entering the regulated area and of their length of stay. This entry roster 
should be maintained as a part of the environmental records.
o-Tolidine should be transported or stored in sealed, intact containers. 
A "sealed container" is one that has been closed and kept closed to the extent 
that there is no release of o-tolidine. An "intact container" is one that has 
not deteriorated or been damaged to the extent that o-tolidine is released. 
It is concluded that sealed, intact containers would pose no threat of 
exposure to employees; therefore, it should not be necessary to comply with 
required monitoring and medical surveillance requirements in operations 
involving such containers. If, however, containers are opened or broken so 
that o-tolidine may be released, then all provisions of the recommended 
standard should apply.
Personnel working in the regulated area should be informed at least 
annually of the nature of the hazard of the compound, the specific nature of 
the operation that could result in exposure, and how to recognize and evaluate 
conditions and situations that may result in the release of o-tolidine. The 
employees should also be informed of all decontamination and emergency 
procedures that apply to their duties and location and especially of their 
role in emergency situations, such as fires or massive spills.
To prevent ingestion of o-tolidine, employees should not be allowed to 
eat, drink, or smoke in the regulated area, and smoking materials, food, or 
beverages should not be stored in this area. To counter unsuspected 
contamination from the container surface and process leaks, employees working 
where o-tolidine is stored in intact, sealed containers or contained in closed 
processes should wash their face, neck, hands, and forearms each time they 
leave the area before they engage in other activities because, even though 
they are wearing clothing that generally provides an effective barrier, leaks 
around sleeves and collars may negate some of the protective value of the 
clothing. Before leaving the regulated area at the end of the workday, 
employees should shower, shampoo, and scrub their fingernails. Users of o- 
tolidine test tapes and test kits need not comply with these provisions. 
Washing facilities should be located close to each exit. If glove boxes are 
used to handle o-tolidine, employees should wash their hands and arms on
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completion of the assigned tasks, as a precautionary measure against possible 
defects in the gloves of the glove box, before engaging in activities not 
related to o-tolidine.
Test tapes, impregnated or coated with o-tolidine, are widely used in 
medical tests, such as monitoring glucose levels in the control of diabetes 
and for the testing of occult blood. In addition to frequent monitoring 
performed by patients themselves, tests are regularly performed by technicians 
in hospitals and clinical laboratories. The concentration of o-tolidine in 
test tapes is reported to be about 0.1 mg/2.5 cm (1 inch) of tape. Assuming 
approximately 0.5 cm of tape comes in contact with the fingers with each test, 
then a maximum amount of 0.02 mg might be absorbed, which is very unlikely. 
Some manufacturers have attached small plastic handles to the test tapes to 
further minimize dermal contact with o-tolidine.
Kits containing o-tolidine in solution are also used extensively by the 
public for testing the chlorine content in water in private swimming pools. 
Occupational use of similar test kits occurs in waste water treatment plants, 
potable water supply companies, and companies that service public and private 
swimming pools on a commercial basis. These test kits are usually prepared by 
taking 10 ml aliquots from 1- to 2-liter acidic (HC1) stock solutions 
containing 0.1% o-tolidine. From the test kit solution, 2-10 drops are added 
to 10 ml of water to be tested, the solution is capped and mixed by inverting 
the container, and then the developed color is compared with that on a 
standard color chart. Assuming there are about 20 drops/ml of water, if 5 
drops of a 0.1% test solution were added to 10 ml of water, there would be 
approximately 0.00125 mg/drop of water being tested. In mixing water 
solutions improperly, an employee sometimes uses the tip of the thumb or 
finger, or possibly the forearm, rather than a cap to cover the opening of the 
container. Exposures are limited to the low o-tolidine concentration 
encountered during the mixing process. On rare occasions, test solutions 
containing 0.5% o-tolidine are used in water sanitizing procedures.
Although o-tolidine is present in test tapes and test kits, it is not 
believed that an occupational hazard exists from dermal contact with o- 
tolidine because of the low quantities available for skin absorption during 
the conduct of these tests.
It is essential that clothing, footwear, and headgear be clean each 
workday to reduce prolonged skin contact with o-tolidine. Each employee in 
the regulated area should therefore put on, at the beginning of each 
workshift, a complete set of clean work clothing (long-sleeved shirt, 
trousers, underwear, and footwear) before entering the regulated area. One 
manufacturer of o-tolidine preferred synthetic fibers to cotton because they 
have found that o-tolidine tends to adhere to cotton even after washing [42]. 
Footwear, including rubber shoes, should be cleaned inside and out at least 
daily and should not be taken home. Hard hats, if worn, should be over
disposable or washable head covers and should be cleaned daily. In addition
to this work clothing, protective clothing, including waterproof gloves and 
aprons or overalls, or a full-body protective suit, should be provided to
employees engaged in operations in which o-tolidine is transferred from a
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closed system or charged or discharged into other normally closed containers, 
in activities involving the opening of a closed system, or in activities 
involving laboratory hoods. This additional protection is believed necessary 
because these operations involve a greater risk of exposure to o-tolidine.
Waterproof gloves and aprons or overalls that are resistant to penetration 
by o-tolidine should be used while working with filters and dryers, while 
handling or decontaminating the exterior of filled barrels of o-tolidine, in 
dropping presses and filters, for taking process samples for quality checks, 
and for performing other routine tasks not involving maintenance. Protective 
clothing requirements for maintenance activities, including cleaning and 
decontamination of equipment and material, should be determined for each job 
by an industrial hygienist and the regulated-area supervisor.
Entry into confined spaces, such as tanks, pits, and process vessels that 
have contained o-tolidine, shall be controlled by a permit system. Permits 
shall be signed by an authorized employer representative certifying that 
prescribed precautionary measures and procedures have been followed. All 
lines should be disconnected or blocked off, and all valves or pumps leading 
to and from the vessel should be locked or tagged out while the vessel is 
being cleaned. The vessel should also be either washed with water and purged 
with air or purged with nitrogen and then with air.
The vessel should then be checked by trained personnel for fire or 
explosion hazard, airborne o-tolidine, possible oxygen deficiency, and 
concentrations of other likely contaminants to assure that no danger exists. 
Mechanical ventilation should be provided continuously when employees are 
inside the vessel. Each employee entering the vessel should be equipped with 
appropriate respiratory protection, a harness, and a lifeline. At least one 
other person, similarly equipped, should observe from outside and should 
maintain effective communication with the employee inside the vessel at all 
times.
As a supplement to engineering controls, a full-body protective suit with 
appropriate respiratory protection and head covering should be provided to 
each employee in such operations as weighing o-tolidine or charging reaction 
vessels for dye, pigment, and urethane manufacture [10] because of the higher 
risk of inhalation and skin contact. Positive pressure supplied-air 
respirators with full facepiece should be used whenever necessary to keep 
worker exposure to the lowest level possible. Full facepieces afford better 
fit to minimize leakage and obviate any possible problems of eye irritation. 
However, because contaminated clothing and equipment are primary sources of 
skin contact with o-tolidine, full-body protective clothing with necessary 
head and face protection should be used with these respirators.
Employees engaged in operations involving o-tolidine should leave their 
protective clothing and equipment at the exit. When workers leave the 
regulated area at the end of the workday, the used protective clothing and
eq-i-yzenz she-Id be placed in clearly labeled containers for decontamination 
or disposal.
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Each employee involved in cleaning up leaks and spills should wear a 
completely enclosed full-body protective suit with either a self-contained 
breathing apparatus or a supplied-air respirator with auxiliary self-contained 
air supply. After the cleanup, the area should be decontaminated and washed, 
the protective clothing and equipment should be decontaminated and removed, 
and the employee should shower. Potassium permanganate and sodium 
hypochlorite have been recommended for decontamination of clothing and 
equipment, but data on their effectiveness as decontaminating agents were not 
provided (JW Meigs, written communication, December 1977). To minimize 
concentrations of airborne o-tolidine, employees should be prohibited from dry 
sweeping and dry mopping in the regulated area. The regulated area should be 
washed thoroughly at the end of each shift. The waste water should be 
collected in holding basins for decontamination with potassium permanganate or 
sodium hypochlorite. One o-tolidine manufacturer wipe tests work surfaces in 
the regulated area (PF Woolrich, written communication, December 1977). 
Quantitative information relating wipe test results with air levels of o- 
tolidine or with toxic effects of o-tolidine is not available, so its 
usefulness as a monitoring tool is unknown.
A clean change room, free of o-tolidine contamination and containing 
locker facilities, should separate regulated and nonregulated areas. The 
clean change room should be separated from the regulated area by a shower 
room. Therefore, with the exception of emergency exits, the movement of 
workers from clean room to regulated area should occur only through the shower 
area. The clean room should be under positive pressure relative to the 
regulated area to prevent accidental contamination of the clean area when 
workers move from one area to the other. Appropriate signs should be posted 
at the entrance informing workers of the procedures for entering and leaving 
the regulated area.
All workers must put on clean work clothing, including underwear, 
trousers, and shirt, along with footwear and the necessary protective 
equipment in the clean room before entering the regulated area. At no time 
should the regulated area be used to store protective equipment because 
accidental contamination by o-tolidine is possible. Before leaving the 
regulated area, workers should remove all protective clothing and equipment 
and wash their hands, forearms, face, and neck. Upon reentering the regulated 
area, the worker must put on the same protective clothing and equipment. To 
minimize traffic from regulated areas to clean areas, employers should locate 
toilets in rooms within regulated areas. Employees in regulated areas should 
wash their hands and forearms before and after using the toilet.
At the end of the workshift, protective clothing and equipment should be 
placed in clearly labeled containers in the regulated area for decontamination 
or disposal. The employees should then proceed to the shower facilities, 
remove all work clothing, and place it in labeled containers for laundering. 
Employees should shower and shampoo with soap or other detergent before 
entering the clean room to put on street clothing.
Laundry contaminated with o-tolidine should be transported only in sealed 
containers. Soap or other detergent should be used to clean work clothing.
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Sodium hypochlorite has been suggested for decontamination of work clothing 
(PF Woolrich, written communication, December 1977). Plant personnel involved 
in laundering should be equipped with aprons and gloves, warned of the hazards 
of o-tolidine, and trained to handle contaminated clothing safely. If an 
outside laundry facility is used, the laundry employer must be advised of the 
hazards involved in handling clothing contaminated with o-tolidine and of the 
requirements to ensure that the laundry employees are not exposed to o- 
tolidine.
Employees who handle only very small quantities of o-tolidine (such as 
users of test tapes and water analysis kits) are considered to be at only 
minimal risk, and therefore the requirements for regulated areas and clean 
room facilities are not deemed necessary. These workers should be adequately 
protected from skin contact and inhalation if they perform all activities 
involving o-tolidine in a laboratory hood or glove box and use long-sleeved 
coveralls or coats and gloves of materials resistant to penetration by o- 
tolidine. Workers should be required to wash their hands, forearms, neck, and 
face with soap and water after working with o-tolidine to guard against 
accidental contamination.
In emergencies, the contaminated area should be evacuated immediately. 
Only personnel trained in emergency procedures and equipped with full-body 
protective clothing and proper respirators should enter the contaminated area 
to make repairs and decontaminate the site. All employees within the affected 
area at the time of emergency should be required to shower promptly. If 
biologic monitoring is performed, it should be conducted within 24 hours.
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VI. DEVELOPMENT OF STANDARD
Basis for Previous Standards
No country has yet published a workplace environmental limit for o- 
tolidine. However, maximum allowable concentration (MAC) limits have been set 
by the Polish government for the chemically related substances benzidine and 
dianisidine (0.01 mg/cu m) [79]. Documentation supporting this value has not 
been found. Belgium, Great Britain, Sweden, and Japan have published work 
practice recommendations for o-tolidine. In Belgium, exposure to o-tolidine 
base (and to benzidine and its salts) is prohibited because o-tolidine is 
considered a carcinogen [80]. The basis for this decision was not given. 
Great Britain established stringent regulations, still in effect, concerning 
the manufacture and use of o-tolidine, which appeared with dianisidine and 
dichlorobenzidine on that country's 1967 controlled substances list [80,81]. 
These regulations are still in effect. The regulations state that all 
precautions must be taken to prevent workers' exposure, and they provide for 
extensive medical examinations every 6 months. The National Board of 
Occupational Safety and Health of Sweden included o-tolidine on a list of 
substances that could be manufactured or used only if special instructions by 
the labor inspectorate were followed [80,82,83]. Similarly, in Japan, special 
permission must be obtained from the labor department to use or manufacture o- 
tolidine. When this permission is granted, strict procedures that prevent 
worker exposure and provide for regular medical examinations must be followed 
[80]. The Soviet Union reportedly no longer produces o-tolidine [84].
Basis for the Recommended Standard
(a) Permissible Exposure Limits
A few studies have been found that give results of human exposure to o- 
tolidine, usually in conjunction with exposure to other related diamines, eg, 
benzidine, dichlorobenzidine, and dianisidine [16,19,21-23,85]. A number of 
animal studies have been found in which the effects of exposure to o-tolidine 
by itself were investigated [17,26,28-30,33,35,38,44,49]. Most occupational 
exposures involve a mixture of biphenyl amine compounds, including benzidine, 
o-tolidine, dichlorobenzidine, and dianisidine [19,21-23].
There is a report stating that inhalation of o-tolidine hydrochloride 
causes nasal irritation in humans [16]. o-Tolidine is absorbed through the 
skin of humans without apparent skin irritation [17] and is subsequently 
eliminated in the urine [17,22],
Although cancer has not been observed in humans exposed to o-tolidine 
alone, workers exposed to a combination of benzidine and o-tolidine have 
developed bladder cancer [20,21]. Benzidine is a known human bladder 
carcinogen [15], but these reports [20,21] do not give sufficient data to 
determine if the cancers were induced by benzidine alone, o-tolidine alone, or 
both compounds.
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o-Tolidine (or its metabolites) is carcinogenic in some animals [29,33-
35]. The majority of rats developing cancers had carcinomas of the Zymbal 
glands, mammary gland adenocarcinomas, and hepatocarcinomas [33-35]. Tumors 
of lesser frequency included skin cancers, stomach papillomas, small intestine 
adenocarcinomas, one uterine leiomyosarcoma, preputial sebaceous gland tumors, 
and reticulosarcomas. One of four dogs fed o-tolidine for 8-9 months 
developed bladder cancer after 8 years [29].
Ames assays showed o-tolidine to be mutagenic in two studies [41,43].
However, another, more comprehensive, study [42] reported negative findings 
for o-tolidine. o-Tolidine was shown to depress thymidine incorporation into 
testicular DNA [40] , indicating a diminution of DNA synthesis directly related 
to o-tolidine exposure. o-Tolidine had mutagenic effects on rat embryo cells 
in cell culture; when the transformed cells were transplanted into rats, they 
developed into tumors [39].
o-Tolidine did not cause deformed rat embryos in dams receiving a total
dose of 30 mg in three successive daily sc injections [45], but 8% of the 
fetuses were resorbed. Organ cultures of embryonic kidneys from pregnant mice 
given sc injections of 2 mg/day for 19-20 days exhibited epithelial 
hyperplasia and "other cellular changes" that were not seen in the controls 
[44]; this suggests that o-tolidine may have transplacental effects on 
embryogenesis.
There are important similarities between o-tolidine and benzidine, a known 
human bladder carcinogen. Structurally, o-tolidine is the 3,3’-dimethyl 
substituted form of benzidine, and its physical and chemical properties 
closely parallel those of benzidine [5,6]. Both are absorbed through human 
skin and are excreted in the urine either unchanged or as structurally 
analogous conjugates [22,47,58]. The metabolic pathways of both are similar; 
both undergo acetylation, hydroxylation, or sulfate esterification 
[22,47,50,56,58]. Neither compound has induced bladder cancer in rats 
[15,62], but each has caused cancer in other tissues and organs [15,62]. 
Bladder cancer in dogs has been observed with each compound [29,86], although 
the evidence for o-tolidine consists of-only one dog with cancer of four dogs 
exposed, 8 years after an 8- to 9-month feeding period [29] .
Because tests with o-tolidine, like benzidine, have resulted in mutagenic 
effects in test systems and because cancer has occurred in rodents as a result 
of o-tolidine absorption, there is substantial reason to believe that o- 
tolidine will induce bladder cancer in humans. Therefore, it is recommended 
that o-tolidine be handled as a suspect human carcinogen. Because of this 
conclusion and since it is not possible at this time to establish an exposure 
level at which o-tolidine is known to be harmless, it is recommended that 
exposure to o-tolidine be kept as low as possible through strict adherence to 
a program of monitoring, engineering controls, and stringent work practices. 
The recommended sampling and analytical method for measuring o-tolidine in air 
is one that has been experimentally confirmed for benzidine and, because of 
the physical and chemical similarities of the two compounds, the method is 
judged to be suitable for o-tolidine. The lowest amount of o-tolidine 
reliably measured quantitatively by this method is estimated to be 0.2
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Mg/sample. If an air sample is collected at 0.2 liters/minute for 60 minutes, 
this quantity of o-tolidine is equivalent to 20/xg/cu m, so this concentration 
represents the lowest level at which a reliable quantitative estimate of 
exposure to o-tolidine can be determined. Therefore, it is recommended that 
occupational exposure be controlled so that no worker will be exposed at a 
concentration of o-tolidine in excess of 20jug/cu m in air determined from an 
air sample collected at 0.2 liters/minute for 60 minutes.
It is of interest that the International Agency for Research on Cancer 
(IARC) has also listed o-tolidine as a cancer suspect agent in humans [87,88].
Although o-tolidine is present in test tapes and test kits used for the 
determination of glucose in blood or urine, blood in urine or feces, or 
chlorine in water, it is not believed that an occupational hazard exists 
either from airborne o-tolidine or from dermal contact that may result from 
such use. It is concluded that users of test tapes and test kits containing 
o-tolidine should be excluded from the monitoring and surveillance 
requirements of this recommended standard. However, all provisions of the 
standard should apply where o-tolidine is used in the manufacturing and 
formulating of test tapes, test kits, and test solutions.
The presence of o-tolidine or its metabolites in the urine provides a 
means for the biologic monitoring of o-tolidine exposure, even though such 
monitoring has not been sufficiently investigated to warrant requiring it as 
part of medical monitoring. However, it may still be a useful adjunct to 
monitoring of the workplace air to gain information on unknown sources of 
exposure, to identify unanticipated excursions, and to recognize poor work 
practices.
(b) Sampling and Analysis
A filter is suitable for capturing the o-tolidine aerosol. The filter 
should be made of glass fibers to minimize pressure drop. The filter should 
be backed by a silica gel tube because o-tolidine has a low but distinct vapor 
pressure. High-pressure liquid chromatography has been shown to be a good 
method for benzidine and should be similarly useful for the analysis of o- 
tolidine.
(c) Medical Surveillance
Comprehensive preplacement and annual examinations should be made 
available to all workers occupationally exposed to o-tolidine. Workers should 
be informed that o-tolidine administration has resulted in nasal irritation in 
humans and that o-tolidine has caused kidney damage [16] or cancer of the 
skin, glands, or internal organs [29,33] in animals.
Because of the possibility of kidney damage [16,26], workers 
occupationally exposed to o-tolidine should have quarterly urine examinations, 
including a complete urinalysis and microscopic examination of the urine for 
evidence of abnormal cells indicative of kidney damage or neoplasms. The
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test should be repeated within 1 week to confirm any abnormal results found. 
If the abnormalities are confirmed, the worker should be referred to a 
physician for a comprehensive urologic evaluation.
(d) Personal Protective Equipment and Clothing
Employees working with o-tolidine change clothes at the beginning and end 
of work shifts. Work clothes may become contaminated with dust, so they must 
be kept in a separate locker, away from street clothes. Clean work clothes 
should be worn each shift. If work clothes are not changed after each shift 
and laundered, absorption of o-tolidine through the skin may be facilitated by 
both the increased time in which skin contact is maintained and by the buildup 
of o-tolidine in the clothing [22] . Measurement of o-tolidine in the urine of 
workers confirmed this in one operation [22] . Soiled work clothes should be
stored in covered containers until they are laundered either at the plant or,
if an outside laundry facility is used, the launderers should be advised of 
the hazards and proper procedures involved in handling contaminated work 
clothing. Sodium hypochlorite has been used for decontamination prior to 
laundering, but no data supporting its effectiveness have been found. The 
employer in charge of laundering should emphasize precautionary measures to 
avoid exposure to o-tolidine from handling contaminated work clothes. Gloves 
and aprons resistant to o-tolidine should be worn, and skin contact with o- 
tolidine should be avoided. When exposure to dust or mist containing o- 
tolidine occurs during emergencies, maintenance operations, or special 
processes, use of the respirators specified in Chapter I, Section 3 (b) and 
full-body skin protection should be observed.
(e) Informing Employees of Hazards
Continuing education is an important part of a preventive hygiene program 
for employees exposed to o-tolidine. Workers should be instructed 
periodically by properly trained persons about possible sources of exposure to 
o-tolidine, engineering and work practice controls in use or being planned to 
limit exposure, and on monitoring procedures used to check control procedures. 
It should also be explained that o-tolidine may be readily absorbed through 
the intact skin as well as by inhalation or ingestion and that exposure to it 
poses a risk of damage to the urinary tract, primarily cancer of the urinary
bladder. The function of environmental monitoring equipment, such as personal
samplers, should be explained, so that employees understand their part in 
environmental monitoring. Medical monitoring procedures and their importance 
in detecting possible adverse health effects should be explained.
(f) Work Practices
Because o-tolidine can be readily absorbed through intact skin and mucous 
membranes, special work practices are essential. It is especially important 
that the use of regulated areas and clean rooms and the procedures for 
sanitation, maintenance, and emergencies in the control of airborne o-tolidine 
be understood and followed by workers occupationally exposed to the chemical.
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If o-tolidine is handled or stored in intact, sealed containers, the 
requirements of regulated areas should not be necessary. However, if 
containers are opened, the requirement for a regulated area applies.
(g) Monitoring and Recordkeeping Requirements
Industrial hygiene surveys should be conducted after the promulgation of a 
standard based on these recommendations and within 14 days of any process 
change.
If the concentration of airborne o-tolidine in a regulated area exceeds 
the recommended occupational exposure limit, proper engineering and work 
practice control measures should be initiated. Sampling should be repeated 
until two consecutive determinations at least 1 week apart show that airborne 
concentrations of o-tolidine are below the recommended occupational exposure 
limit. If this survey reveals that the airborne concentration is below the 
recommended occupational exposure limit, then the survey need only be repeated 
annually.
Medical records for all employees occupationally exposed to o-tolidine 
should be kept for 30 years after the termination of employment. Records of 
environmental exposures to o-tolidine should be included with the worker's 
medical records. These records should be available to the designated medical 
representatives of the employer, employee, Secretary of Health, Education, and 
Welfare, and of the Secretary of Labor.
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VII. RESEARCH NEEDS
Although o-tolidine Is not a new compound and has been used for a century 
as an indicator in analytical chemistry and as an intermediate in the 
synthesis of approximately 100 dyes [4], relatively little has been published 
about its effects on biologic systems. In particular, there is a scarcity of 
information on how o-tolidine affects humans.
Before better dose-response relationships can be delineated, more 
experiments with animals are needed. As presented in Chapter III, the 
currently available experimental data on rats exposed to o-tolidine indicate 
that, as with benzidine, it can cause cancer in a number of organ systems in 
the rat, but it does not cause bladder cancer. This is also apparently true 
for the hamster. Attempts should be made to find an animal model in which 
bladder cancer could be identified from administration of o-tolidine, 
benzidine, or other diphenyl amines. This would be helpful in evaluating 
bladder cancer in humans associated with these amines. Epidemiologic studies 
on workers exposed to o-tolidine are especially needed to investigate the 
problem of o-tolidine-related bladder tumors in humans. Cell- and organ- 
culture studies, including host-mediated assays, would be useful to evaluate 
the significance of genetic alterations from o-tolidine. The renal effects 
from o-tolidine, both alone and associated with exposure to other chemicals, 
especially other aromatic amines, should be addressed.
The metabolism of o-tolidine resembles that of benzidine, a known human
bladder carcinogen. Additional studies are needed to further elucidate o-
tolidine metabolism, to compare it to that of benzidine, and to identify those
metabolites that may be toxic or carcinogenic. The possibility exists that
dyes made from o-tolidine might release free o-tolidine in the body. This 
should be investigated.
Workers who use o-tolidine coated or impregnated test tapes or water 
analysis test kits containing o-tolidine are judged at this time to be at 
negligible risk from the chemical. (This is based on professional estimates 
and calculations because investigative data are lacking.) Studies should be 
conducted to ascertain whether such users absorb o-tolidine from skin contact 
in quantities sufficient to pose a risk to worker health.
Validation of the sampling and analytical methods recommended for o- 
tolidine is needed, even though they have been tested for benzidine and are 
judged to be effective for o-tolidine.
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This method for sampling and analysis of o-tolidine is adapted from the 
NIOSH Manual of Analytical Methods, Method No. 243, for benzidine and 
benzidinium sulfate [67]. Although the method has not been validated for o- 
tolidine, it has been used successfully to analyze for other biphenyl amines 
and is judged to be acceptable for o-tolidine.
Principle of the Method
A known volume of air is drawn through a two-stage sampler consisting of a 
high-efficiency glass fiber filter followed by a bed of silica gel to collect 
o-tolidine and its salts. The glass fiber filter is recommended to minimize 
pressure drop. The filter and sorbent sections of the sampler are transferred 
to stoppered tubes and the o-tolidine desorbed. A solution of triethylamine 
in methyl alcohol is used for benzidine and should be successful for o- 
tolidine also. An aliquot of this solution is injected into a high-pressure 
liquid chromatograph (HPLC). Peak areas are determined and compared with a 
calibration curve obtained from injections of standard solutions of o- 
tolidine.
Range and Sensitivity
This method can detect 0.15-6.5 jug of benzidine/sample (3-130 Mg/cu m for 
a 50-liter air sample) using 0.5 ml of desorbing solution and a 10-^1
injection into the liquid chromatograph. The range of detection for o-
tolidine should be similar. The upper limit can be extended by increasing the 
volume of desorbing solvent as a diluent, decreasing the sensitivity of the 
detector, or decreasing the aliquot injected into the liquid chromatograph. 
The limit of detection for o-tolidine is not known but is expected to be
similar to that of benzidine, which is 0.05 jug/sample.
Interferences
Any compound sampled with o-tolidine and having the same retention time as 
o-tolidine interferes with the analysis. This type of interference often can 
be minimized by changing the operating conditions of the chromatograph, eg, by 
changing the composition of the mobile phase or by solvent programming.
Precision and Accuracy
Filters spiked with benzidine or its salts and stored at -15 C showed 97- 
98% recovery after 11 days. Recovery tended to decrease with increased
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storage time. o-Tolidine recovery should be similar to that of benzidine. 
The precision of this method for benzidine is 7% relative standard deviation 
for concentrations of benzidine of 21-63 jug/cu m of air. The accuracy of the 
method has not been determined.
Advantages and Disadvantages of the Method
The sampler is small, portable, contains no liquids, and can be used to 
sample the air in the breathing zone of a worker. Temperature and humidity do 
not significantly affect the method. Desorption of the collected sample is 
simple and the analysis is accomplished by a rapid instrumental technique. 
Possible interferences can be obviated by changing the composition of the 
mobile phase or by solvent programming.
At a flowrate of 0.2 liter/minute, the linear velocity through the 4-mm 
inlet of the filter holder is 26.5 cm/second. It is not known if this is 
sufficient to capture all important particles. The method has not been field 
tested.
Apparatus
(a) Calibrated personal air sampling pump that can be maintained for 60
minutes at a flowrate of 0.2 liter/minute with the sampler in line.
(b) Sampler (Figure IX-1). The sampler consists of two sections, a high- 
efficiency glass fiber filter and a 50-mg bed of silica gel. The first
section, a 13-mm type A-E glass fiber filter, is contained in a 13-mm filter
holder. The sorbent tube is a 30-mm section of Pyrex glass, 6.4-mm O.D. x 4-
mm I.D., flared on one end, containing 50 mg of GC grade silica gel (D-08, 
30/60 mesh, 720-760 sq m/g, 4.3 g/cc). The sorbent is held by 3.5-mm
diameter, 100-mesh stainless steel screens and 4-mm O.D. Teflon rings. To 
connect the two stages, the filter holder is pressed into the flared end of 
the sorbent tube. Plastic caps of 6-mm I.D. seal the ends of the sampler.
(c) Insulated container suitable for transporting samples packed in dry
ice.
(d) Dry ice.
(e) HPLC equipped with an ultraviolet detector (254 nm) and injection
valve.
(f) juBondapak C18 column (10-/im) , 4.0-mm I.D. x 30-cm or equivalent.
(g) Potentiometer strip chart recorder.






(i) Glass syringes, 10 fil.
(j) Pipets of convenient sizes for the preparation of standard
solutions.




(n) Test-tube shaker (vortex type).
Reagents
All reagents should be of analytical reagent quality or better.
(a) Methyl alcohol (UV grade), distilled in glass.
(b) Water, distilled.
(c) Mobile phase: 3/2 (v/v) methyl alcohol in water.
(d) Triethylamine.
(e) Desorbing solution: triethylamine in methyl alcohol, 0.17% (v/v).
(f) o-Tolidine, analytical standard quality.
Procedure
(a) Cleaning of Equipment
All glassware used for the laboratory analysis is washed with detergent, 
rinsed with tap water, distilled water, and methyl alcohol, and dried in an 
oven.
(b) Calibration of Personal Sampling Pumps
Each pump should be calibrated with a representative sampler in line to 
minimize errors in volume measurement. A bubble flowmeter or other suitable 
flow measuring device may be used.
(c) Collection and Shipping of Samples
(1) Immediately before sampling, the plastic caps are removed from 
the end of the sampler and saved for resealing after sampling.
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(2) The sorbent end of the sampler is connected to the pump with 
plastic or rubber tubing. The sampler is positioned vertically during 
sampling. Sampled air must not pass through any tubing before entering the 
sampler.
(3) The atmosphere is sampled at a flowrate of 0.2 liter/minute for 
60 minutes. The flowrate and sampling time, or the volume of sampled air, 
must be measured as accurately as possible.
(4) The temperature, pressure, and humidity of the atmosphere being 
sampled is measured and recorded.
(5) The sampler is resealed with the plastic caps immediately after
sampling.
(6) Blank samples are obtained by handling random collection devices 
in the same manner as in sampling, except that no air is drawn through them.
(7) Samples shipped to the laboratory should be packed tightly to 
minimize breakage and cooled with dry ice.
(8) If samples of bulk material associated with the process under 
investigation are to be shipped to the laboratory, they should not be placed 
in the same container as the air samples or blanks.
(9) The samples should be stored at temperatures at or below -15 C
prior to analysis. Because of the possible instability of the analyte, the
samples should be analyzed as soon as possible after collection.
(d) Analysis of Samples
(1) Preparation of samples. Place the glass fiber filters and 
silica gel in separate 1-ml test tubes or other suitable vials. Teflon rings 
and stainless steel screens associated with the samplers may be analyzed with 
the appropriate stages or rinsed with the desorbing solution. Sampler caps 
can be discarded.
(2) Desorption of samples. Add 0.5 ml of desorbing solution to each 
vial containing a sampler stage. Cap the vials and shake them with a test- 
tube shaker. Allow them to stand for 1 hour with intermittent shaking. 
Centrifuge for 10 minutes. Treat blanks in the same manner.
(3) Liquid chromatographic conditions. The following conditions
work for benzidine and may have to be modified to obtain proper separation of
o-tolidine.
(A) Column: pBondapak C18 (30 cm x 4.0 mm I.D.).
(B) Mobile phase: Methyl alcohol/water, 3/2(v/v).
(C) Flowrate: 1.5 ml/minute, 1200 psi.
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(D) Temperature: 23 C.
(E) Detector: UV (254 nm), 0.04 absorbance units full scale.
(F) Injection volume: 10 /ul.
(G) Power of separation: 784 theoretical plates.
(H) Capacity ratio: 2.4.
(4) Injection. Flush the 10-jul syringe first with methyl alcohol 
and then with the sample solution. Carefully draw 10 jul of sample solution 
into the syringe to minimize the intake of particulate matter and inject into 
the HPLC. No more than 3% difference in peak areas for replicate injections 
is to be expected.
(5) Measurement of peak area. The area of the sample peak is either 
measured manually or with an electronic integrator. Preliminary results are 
read from a standard curve prepared as discussed below.
(e) Desorption Efficiency
(1) Importance of determination. The desorption efficiencies for o- 
tolidine and its salts can vary from one laboratory to another and also from 
one batch of silica gel or filters to another. Thus, it is necessary to 
determine the percentage of o-tolidine that can be recovered from these 
matrices. The desorption efficiency may also vary with the amount of o- 
tolidine present; therefore, measurements should be made for at least two 
amounts in the range of the sample size.
(2) Procedure for determining desorption efficiency. Place the 
filters and silica gel from unused samplers in separate 1-ml test tubes. Add 
to each a known amount of o-tolidine in 10-;itl of methyl alcohol using the same 
microliter syringe for each. Five filter and silica gel samples are thus 
prepared at each of two different levels in the range of interest. Cap the 
tubes and allow them to stand overnight to assure complete adsorption of the 
amine on the matrix. Treat a parallel blank in the same manner. Desorb and 
analyze samples and blanks as described above. Prepare two or three standards 
at these same levels by injecting 10 ¡il (same syringe as above) of the o- 
tolidine solutions into 0.5 ml of desorbing solution. Analyze these solutions 
and determine the desorption efficiency.
Calibration and Standards
For accuracy in the preparation of standards, it is recommended that one 
standard be prepared in a relatively large volume and at a high concentration. 
The initial standard is prepared by weighing a selected amount of o-tolidine, 
eg, 125 mg, into a 250-ml volumetric flask and adding the desorbing solution 
to the calibration mark. Dilutions encompassing the concentration range of 
interest down to 0.3 ng//ul are then made from the stock solution.
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CAUTION: o-Tolidine is a suspected carcinogen. Appropriate precautions must
be taken in handling this compound to avoid personnel exposure and area
contamination.
The standard solutions should be analyzed under the same liquid
chromatographic conditions and during the same time period as the samples. 
This will minimize the effect of variations of the detector response or the
mobile phase. A standard curve for o-tolldine is prepared by plotting the
average peak area for a standard against the concentration of the standard in 
jug/0.5 ml.
Calculations
If the blank produces a peak with the same retention time as o-tolidine, 
the analyst should determine the source of the interference and eliminate or 
compensate for it. Read the mass (M) in of o-tolidine present in the 
sample from the calibration curve. The corrected mass (W) is determined by:
W = M 
D
where D is the desorption efficiency for that sampler stage.I
Add the masses of o-tolidine found in the two sampler stages to determine 
the total mass (W) collected. The concentration of o-tolidine in air (C) in 
jug/cu m is given by:
C = W x 1,000 
V
where W is the total mass collected in jug and V is the sampling volume in liters.




ANALYSIS OF URINE SAMPLES USING FLUORESCAMINE
This method for analyzing o—tolidine in urine samples is adapted from the 
method described by Rinde [71].
Principle of the Method
A known volume of urine sample is extracted first with chloroform, then 
with 0.01 M hydrochloric acid to concentrate the o-tolidine. Fluorescamine 
solution is added to the sample followed by methanol to produce a yellow 
product. The optical density is determined at the wavelength of maximum 
absorption, 390 ran, and compared with the calibration curve obtained from 
standard solutions of o-tolidine.
Range and Sensitivity
This method can detect 0.2-5.0 ng of o-tolidine/sample of urine. For 
amounts greater than 5 Mg» suitable dilutions of the sample are required. The 
limit of detection of the method is 0.2 Mg/sample.
Interferences
The method is nonspecific, so any biphenyl amine other than o-tolidine may 
interfere with the analysis. This interference can be- eliminated by using 
thin-layer chromatography to separate the biphenyl amines before adding the 
fluorescamine reagent.
Advantages and Disadvantages of the Method
Cleanup of the collected urine sample is simple, and analysis is 
accomplished by a rapid, instrumental technique. The fluorescamine reagent is 
colorless, so there is no need to extract the unreacted reagent.
The method is nonspecific without prior separation; the various compounds 
cannot be distinguished when o-tolidine occurs in a mixture with other 
biphenyl amines. This can be overcome by using paper or thin-layer 
chromatography to separate the biphenyl amines. However, this procedure is 
tedious and time consuming.
Apparatus
(a) Spectrophotometer with quartz cuvettes.
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(b) Vortex mixer.
(c) Pipetes of convenient sizes to prepare standard solutions.
(d) Volumetric flasks of convenient sizes to prepare standard solutions.
(e) Glass test tubes, 12 x 75 mm.
Reagents
All reagents should be of analytical reagent quality or better.
(a) Fluor es c amine.
(b) Glacial acetic acid.
(c) Methanol.
(d) Chloroform.
(e) Hydrochloric acid, 0.01 M.




(a) Cleaning of Equipment
All glassware used for the laboratory analysis is washed with detergent, 
rinsed with tap water, distilled water, and methanol, and dried in an oven.
(b) Analysis of Samples
(1) Extraction of samples. Adjust the pH of the sample (100 ml) to 
5-6, extract first with chloroform, then with 0.01 M hydrochloric acid. 
Readjust the pH of the HC1 solution, and extract again with chloroform.
(2) Preparation of fluorescamine solution. Dissolve fluorescamine 
in glacial acetic acid (1 mg reagent/ml acid) to make the fluorescamine 
solution.
(3) Preparation of assay cuvettes. Evaporate the chloroform extract 
to dryness in 12 x 75 mm tubes using nitrogen gas. Add 50 ¡j.1 of fluorescamine 
solution and mix for 30 seconds. After 10 minutes, add 0.5 ml methanol. Wait 
10 minutes for full color development, then transfer to cuvette.
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(4) Spectrophotometry. Set the spectrophotometer to 390 nm. Using 
a suitable blank of chloroform, adjust the optical density scale to zero.
(5) Measurement of o-tolidine concentration. Place the sample 
cuvete in the spectrophotometer and measure the optical density. Read
preliminary results from a standard curve prepared as discussed below.
Calibration and Standards
For accuracy in the preparation of standards, it is recommended that one 
standard be prepared in a relatively large volume and at a high concentration. 
Prepare the initial standard by pouring a selected amount of o-tolidine, eg, 
125 mg, into a 250-ml volumetric flask and adding chloroform to the 
calibration mark. Make dilutions encompassing the concentration range of 
interest down to 0.3 ng//il from the stock solution.
CAUTION: o-Tolidine and chloroform are suspected carcinogens. Appropriate
precautions must be taken in handling these compounds to avoid personnel 
exposure and area contamination.
The standard solutions should be analyzed at the same time as the samples.
This will minimize the effect of variations of the spectrophotometer's
response. Prepare a standard curve for o-tolidine by plotting the optical 
density for a standard against the concentration of the standard in jug.
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XI. APPENDIX III
MATERIAL SAFETY DATA SHEET
The following items of information that are applicable to a specific 
product or material shall be provided in the appropriate block of the Material 
Safety Data Sheet (MSDS).
The product designation is inserted in the block in the upper left corner 
of the first page to facilitate filing and retrieval. Print in upper case 
letters as large as possible. It should be printed to read upright with the 
sheet turned sideways. The product designation is that name or code 
designation which appears on the label, or by which the product is sold or 
known by employees. The relative numerical hazard ratings and key statements 
are those determined by the rules in Chapter V, Part B, of the NIOSH 
publication, An Identification System for Occupationally Hazardous Materials. 
The company identification may be printed in the upper right corner if 
desired.
(a) Section I. Product Identification
The manufacturer's name, address, and regular and emergency telephone 
numbers (including area code) are inserted in the appropriate blocks of 
Section I. The company listed should be a source of detailed backup 
information on the hazards of the material(s) covered by the MSDS. The 
listing of suppliers or wholesale distributors is discouraged. The trade name 
should be the product designation or common name associated with the material. 
The synonyms are those commonly used for the product, especially formal 
chemical nomenclature. Every known chemical designation or competitor's trade 
name need not be listed.
(b) Section II. Hazardous Ingredients
The "materials" listed in Section II shall be those substances that are
part of the hazardous product covered by the MSDS and individually meet any of
the criteria defining a hazardous material. Thus, one component of a 
multicomponent product might be listed because of its toxicity, another
component because of its flammability, while a third component could be
included both for its toxicity and its reactivity. Note that a MSDS for a 
single component product must have the name of the material repeated in this 
section to avoid giving the impression that there are no hazardous 
ingredients.
Chemical substances should be listed according to their complete name 
derived from a recognized system of nomenclature. Where possible, avoid using 
common names and general class names such as "aromatic amine," "safety 
solvent," or "aliphatic hydrocarbon" when the specific name is known.
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The "%" may be the approximate percentage by weight or volume (indicate 
basis) which each hazardous ingredient of the mixture bears to the whole 
mixture. This may be indicated as a range or maximum amount, ie, "10-40% vol" 
or "10% max wt" to avoid disclosure of trade secrets.
Toxic hazard data shall be stated in terms of concentration, mode of 
exposure or test, and animal used, eg, "100 ppm LC50-rat," "25 mg/kg LD50- 
skin-rabbit," "75 ppm LC man," or "permissible exposure from 29 CFR
1910.1000," or, if not available, from other sources of publications such as 
the American Conference of Governmental Industrial Hygienists or the American 
National Standards Institute Inc. Flashpoint, shock sensitivity, or similar 
descriptive data may be used to indicate flammability, reactivity, or similar 
hazardous properties of the material.
(c) Section III. Physical Data
The data in Section III should be for the total mixture and should include 
the boiling point and melting point in degrees Fahrenheit (Celsius in
parentheses); vapor pressure, in conventional millimeters of mercury (mmHg); 
vapor density of gas or vapor (air = 1); solubility in water, in parts/hundred 
parts of water by weight; specific gravity (water = 1); percent volatiles 
(indicated if by weight or volume) at 70 F (21.1 C); evaporation rate for
liquids or sublimable solids, relative to butyl acetate; and appearance and
odor. These data are useful for the control of toxic substances. Boiling
point, vapor density, percent volatiles, vapor pressure, and evaporation are 
useful for designing proper ventilation equipment. This information is also 
useful for design and deployment of adequate fire and spill containment 
equipment. The appearance and odor may facilitate identification of 
substances stored in improperly marked containers, or when spilled.
(d) Section IV. Fire and Explosion Data
Section IV should contain complete fire and explosion data for the
product, including flashpoint and autoignition temperature in degrees 
Fahrenheit (Celsius in parentheses); flammable limits, in percent by volume in 
air; suitable extinguishing media or materials; special firefighting 
procedures; and unusual fire and explosion hazard information. If the product 
presents no fire hazard, insert "NO FIRE HAZARD" on the line labeled 
"Extinguishing Media."
(e) Section V. Health Hazard Information
The "Health Hazard Data" should be a combined estimate of the hazard of 
the total product. This can be expressed as a TWA concentration, as a 
permissible exposure, or by some other indication of an acceptable standard. 
Other data are acceptable, such as lowest LD50 if multiple components are 
involved.
Under "Routes of Exposure," comments in each category should reflect the 
potential hazard from absorption by the route in question. Comments should
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indicate the severity of the effect and the basis for the statement if 
possible. The basis might be animal studies, analogy with similar products, 
or human experiences. Comments such as "yes" or "possible" are not helpful. 
Typical comments might be:
Skin Contact— single short contact, no adverse effects likely;
prolonged or repeated contact, possibly mild irritation.
Eye Contact— some pain and mild transient irritation; no corneal
scarring.
"Emergency and First Aid Procedures" should be written in lay language and 
should primarily represent first-aid treatment that could be provided by 
paramedical personnel or individuals trained in first aid.
Information in the "Notes to Physician" section should include any special 
medical information which would be of assistance to an attending physician 
including required or recommended preplacement and periodic medical 
examinations, diagnostic procedures, and medical management of overexposed 
employees.
(f) Section VI. Reactivity Data
The comments in Section VI relate to safe storage and handling of
hazardous, unstable substances. It is particularly important to highlight 
instability or incompatibility to common substances or circumstances, such as 
water, direct sunlight, steel or copper piping, acids, alkalies, etc.
"Hazardous Decomposition Products" shall include those products released under 
fire conditions. It must also include dangerous products produced by aging, 
such as peroxides in the case of some ethers. Where applicable, shelf life 
should also be indicated.
(g) Section VII. Spill or Leak Procedures
Detailed procedures for cleanup and disposal should be listed with
emphasis on precautions to be taken to protect employees assigned to cleanup 
detail. Specific neutralizing chemicals or procedures should be described in 
detail. Disposal methods should be explicit including proper labeling of 
containers holding residues and ultimate disposal methods such as "sanitary 
landfill" or "incineration." Warnings such as "comply with local, state, and 
Federal antipollution ordinances" are proper but not sufficient. Specific 
procedures shall be identified.
(h) Section VIII. Special Protection Information
Section VIII requires specific information. Statements such as "Yes," 
"No," or "If necessary" are not informative. Ventilation requirements should 
be specific as to type and preferred methods. Respirators shall be specified
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as to type and NIOSH or MSHA (Mine Safety and Health Administration) approval 
class, ie, "Supplied air," "Organic vapor canister," etc. Protective 
equipment must be specified as to type and materials of construction.
(i) Section IX. Special Precautions
"Precautionary Statements" shall consist of the label statements selected 
for use on the container or placard. Additional information on any aspect of 
safety or health not covered in other sections should be inserted in Section
IX. The lower block can contain references to published guides or in-house 
procedures for handling and storage. Department of Transportation markings 
and classifications and other freight, handling, or storage requirements and 
environmental controls can be noted.
(j) Signature and Filing
Finally, the name and address of the responsible person who completed the 
MSDS and the date of completion are entered. This will facilitate correction 
of errors and identify a source of additional information.
The MSDS shall be filed in a location readily accessible to employees 
exposed to the hazardous substance. The MSDS can be used as a training aid 
and basis for discussion during safety meetings and training of new employees. 
It should assist management by directing attention to the need for specific 
control engineering, work practices, and protective measures to ensure safe 
handling and use of the material. It will aid the safety and health staff in 
planning a safe and healthful work environment and in suggesting appropriate 
emergency procedures and sources of help in the event of harmful exposure of 
employees.
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PHYSICAL AND CHEMICAL PROPERTIES OF o-TOLIDINE AND BENZIDINE
Property o-Tolidine Benzidine
Holecular fortmla (CH3C6H3NH2)2 (C6H4N-H2)2
Foroula weight 212.32 184.32
Appearance Vhite-to-brovnish 
leaves or crystals, 
often used In paste 
or wet cake form
White or reddish 
crystalline powder
Melting point (base) 129-131 C 115-128 C
Solubility in water at 25 C
Base 1.3 mg/ml 0.52 cg/ml
Dihydrochloride salt 76.7 mg/ml 61.7 ng/nl
Excitation wavelength
Base 300 no 295 no
Dihydrochloride salt 310 run 302 no
Emission wavelength
Base 384 na 396 no
Dihydrochloride salt AIO na 410 na
p-Value* with
Kexane-acetonitrile 0.01 0.02
Hexane-802 acetone, 201 water 0.16 0.08







chloric acid 0.0 0.0
TLC Rf value with
Chlorofore 14 10
Chloroforo-nethanol (9/1, v/v) 80 70
Benzene 2 2
Benzene-aethanol (9/1, v/v) 45 33
♦Fractional acount partitioning into the nonpolar phase of an equal-voluee, 
tvo-phase systeo.
Adapted fron references 1»2,5,6
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TABLE XII-2
OCCUPATIONS WITH POTENTIAL EXPOSURE TO o-TOLIDINE




Forest service chemists 
Glucose diagnostic tape makers 
Leather dye workers 
Medical laboratory workers 
Organic chemists 
o Tolidine makers 
Sanitarians
Sewage treatment plant workers 
Swimming pool test kit makers 
Swimming pool service personnel 
Textile dryers 
Toluene diisocyanate makers 
Urethane curers 
Waterworks attendants 
Adapted from reference 4
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